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ABSTRACT  
   
With the development of computer and sensing technology, rich datasets have 
become available in many fields such as health care, manufacturing, transportation, just to 
name a few. Also, data come from multiple heterogeneous sources or modalities. This is a 
common phenomenon in health care systems. While multi-modality data fusion is a 
promising research area, there are several special challenges in health care applications. (1) 
The integration of biological and statistical model is a big challenge; (2) It is commonplace 
that data from various modalities is not available for every patient due to cost, accessibility, 
and other reasons. This results in a special missing data structure in which different 
modalities may be missed in “blocks”. Therefore, how to train a predictive model using 
such a dataset poses a significant challenge to statistical learning.  (3) It is well known that 
different modality data may contain different aspects of information about the response. 
The current studies cannot afford to solve this problem. My dissertation includes new 
statistical learning model development to address each of the aforementioned challenges 
as well as application case studies using real health care datasets, included in three chapters 
(Chapter 2, 3, and 4), respectively. Collectively, it is expected that my dissertation could 
provide a new sets of statistical learning models, algorithms, and theory contributed to 
multi-modality heterogeneous data fusion driven by the unique challenges in this area. Also, 
application of these new methods to important medical problems using real-world datasets 
is expected to provide solutions to these problems, and therefore contributing to the 
application domains.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
With the development of computer and sensing technology, rich datasets have 
become available in many fields such as health care, manufacturing, transportation, just to 
name a few. Also, data come from multiple heterogeneous sources or modalities. This is a 
common phenomenon in health care systems. Here we give two examples:  
• In neurological disease diagnosis, such as the Alzheimer’s disease (AD), imaging 
of different modalities provides important and complementary roles. For example, 
magnetic resonance imaging (MRI) is used to identify structural changes of the 
brain. Positron emission tomography (PET) imaging is used to identify functional 
alteration. In addition to imaging, other data modalities such as genetics and 
cognitive tests also provide important value. 
• In radiation oncology, it is an important task to predict radiation toxicity for patients 
receiving radiation therapy (RT). Various modalities of data can be integrated to 
accomplish this task, such as radiation dose map, patient demographics, disease 
characteristics, and concurrent treatment.  
    Because each data modality contains unique and usually only partial information 
about the medical problem of interest, statistical learning models based on a single 
modality can rarely achieve optimal results. Multi-modality data fusion can leverage 
the joint strength of different modalities and provide a better solution.  
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1.2 Challenges and Expected Original Contributions 
While multi-modality data fusion is a promising research area, there are several 
special challenges in health care applications.  
Challenge I (Integration of biological and statistical models): While statistical models 
can be used to model any data modality in the general sense, biological models may exist 
for some modality. For example, to predict rectal toxicity for prostate cancer patients 
receiving radiation therapy, a biological model called the Lyman-Kutcher-Burman (LKB) 
model exists, which is based on normal the understanding of normal tissue cells’ response 
to injury by ionizing radiation. Biological models contain existing knowledge of the 
problem of interest, in this case, how radiation dose affects toxicity, but may be based on 
simplified assumptions. Statistical models, on the other hand, are data-driven, and can 
leverage the useful information in the data to the maximum extent, but may be limited in 
obeying biological constraints and providing biological insights or valid interpretation. 
Therefore, how to combine biological and statistical models is a significant challenge in 
multi-modality data fusion.  
Expected original contribution to address Challenge I: We proposed a bio-statistical 
hybrid model for integration of 3-D dose map and patient characteristics in prediction of 
rectal toxicity of prostate cancer patients receiving intensity modulated radiation therapy 
(IMRT). Here, the 3-D dose map is considered a data modality and patient characteristics 
including demographics, disease characteristics, and concurrent treatment are considered 
another data modality because the latter takes a conventional vector format but the former 
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is 3-D data. Our goal is to preserve the biological knowledge in the LKB model, and 
meanwhile use statistical modeling strategies to allow for inclusion of patient-specific 
variables and to better account for patient heterogeneity in the predictive model. The 
integrated approach is expected to have better generalizability and predictive power than 
using biological and statistical models in separation.  
Challenge II (Modality-wise missing data):  It is commonplace that data from various 
modalities is not available for every patient due to cost, accessibility, and other reasons. 
For example, in AD diagnosis, MRI is almost available to all the patients because it is part 
of the routine clinical care. However, FDG-PET may only be available to some patients 
but not all because the equipment is more expensive and not available in some clinics. 
Some newly emerged imaging modalities such as amyloid-PET is not covered by some 
patients’ medical insurance so they may also be unavailable to some patients. This results 
in a special missing data structure in which different modalities may be missed in “blocks”. 
Therefore, how to train a predictive model using such a dataset poses a significant 
challenge to statistical learning.  
Expected original contribution to address Challenge II: A commonly considered 
approach when there is missing data present in a training dataset is to use missing data 
imputation algorithms. However, this is not appropriate for datasets with modality-wise 
missing patterns (i.e., data is missed in blocks as above mentioned), because imputation 
algorithms typically assume the data is missing at random, which is violated in our problem. 
Also, there is too much missing data. Imputation will result in a training set with poor 
quality. We proposed a transfer learning model for integrating multi-modality data with 
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modality-wise missing patterns. Different from missing data imputation, our transfer 
learning model does not fill in missing data but utilize whatever data that is available to 
build a predictive model for each sub-cohort of patients with the same availability of 
imaging modalities. In this way, knowledge obtained from the modeling of each sub-cohort 
can be “transferred” to help the modeling of other sub-cohorts.  
Challenge III: It is well known that different modality data may contain different aspects 
of information about the response. For instance, when assessing the heart toxicity among 
lung cancer patients after RT, the 3-D radiation dose map and patient characteristics are 
often used. The fusion of the two modalities appears to extract dosimetric/volumetric 
features from 3-D dose map and combine the features with patient characteristics in the 
recent studies. However, the extracted dosimetric features lost the spatial information of 
the radiation dose on heart. Clinicians also want to explore the heart sub-region to the high 
radiation dose, which is also called hotspot, that is associated with the heart toxicity. This 
spatial information is contained in the 3-D dose map, which requires researchers to figure 
out. The current studies cannot afford to solve this problem. Moreover, the 
dosimetric/volumetric features were determined under exhaustive search, which may cost 
too much computational time.  
Expected original contribution to address Challenge III: We proposed a hotspot search 
algorithm for the fusion of 3-D radiation dose map and patient characteristics to predict the 
overall survival of the patients. The proposed algorithm divided the 3-D heart dose map 
into several regions, determined the dosimetric/volumetric features in each sub region and 
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finally identified the hotspots of the heart which is associated with overall survival given 
the patient characteristics.  
1.3 Dissertation Outline 
My dissertation includes new statistical learning model development to address 
each of the aforementioned challenges as well as application case studies using real health 
care datasets, included in three chapters (Chapter 2, 3, and 4), respectively. Collectively, it 
is expected that my dissertation could provide a new sets of statistical learning models, 
algorithms, and theory contributed to multi-modality heterogeneous data fusion driven by 
the unique challenges in this area. Also, application of these new methods to important 
medical problems using real-world datasets is expected to provide solutions to these 
problems, and therefore contributing to the application domains.  
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CHAPTER 2 
 
A BIO-STATISTICAL HYBRID MODEL FOR INTEGRATION OF DOSE MAP AND 
PATIENT CHARACTERISTICS WITH APPLICATION IN RADIATION TOXICITY 
PREDICTION OF PROSTATE CANCER 
 
2.1 Introduction 
Radiation therapy (RT) is one of the most common treatments for cancer, either by 
itself or together with other forms of treatments. While the goal of RT is tumor control, it 
is also important in RT planning to spare the normal (surrounding) tissue from radiation 
toxicity that could greatly affect patients’ quality of life.  To understand the impact of 
radiation toxicity on normal tissue, a model is needed to link radiation dose of the RT with 
radiation-induced complications. This is known as the Normal Tissue Complication 
Probability (NTCP) model. There are two types of NTCP models: biological models and 
statistical models. Biological models are built upon the understanding of normal tissue cells’ 
response to injury by ionizing radiation. Typical works include the Lyman model (Lyman, 
1985), the Lyman-Kutcher-Burman (LKB) model (Deasy, 2000), the generalized Lyman 
model (Tucker et al., 2008), and the relative seriality model (Källman et al., 1992). 
Statistical models aim to associate features of radiation dose distribution among the 
receiving tissue with the risk of developing certain complications. There are many 
statistical models to choose from, since this is a typical classification/prediction problem 
in statistics so that theoretically speaking, any classification/prediction algorithm can be a 
potential candidate. Statistical models have been popularly used in recent years for NTCP 
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modeling (Cella et al., 2013; Liu et al., 2010; Michalski et al., 2010; Gulliford et al., 2012; 
Boomsma et al., 2012). 
Next, we will discuss the advantages and disadvantages of biological and statistical 
models. One of the most important advantages for biological models is that the results can 
be generalized beyond a particular study, because biological models are built upon 
radiobiological principles. This provides convenience for clinical utilization, as clinicians 
may refer to published results when they do not have the data to build a biological model 
for their specific practice. Yet, the current knowledge about the biological reaction to 
radiation is still limited. As a result, biological models usually have a low accuracy in 
predicting the risk of radiation-induced complications. Another major contributor to the 
low prediction accuracy is the lack of “personalization”, i.e., biological models do not 
factor in patient-specific information when linking radiation dose with complications. 
However, mounting evidence has shown that even with the same radiation dose distribution, 
different patients have different susceptibility to radiation toxicity and thereby different 
risks of developing complications (Cella et al., 2013; Boomsma et al., 2012).  
In contrast, statistical models have the flexibility of incorporating patient-specific variables 
in addition to radiation dosimetric variables as predictors. In fact, modern development in 
statistics especially machine learning makes it possible to include a large collection of 
patient-specific variables such as demographics, health conditions, and even genetic and 
epigenetic markers. This enables a truly personalized approach in NTCP modeling. In 
addition to personalization, statistical models can account for the special RT data 
characteristics better. One distinct characteristic of the RT data is that the sample fraction 
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of a complication (i.e., the fraction of patients with the complication in the sample dataset 
used for statistical modeling) is typically much larger than the population fraction of the 
complication. This is because the latter fraction is usually a very small number (otherwise, 
the RT would not be permitted for practice). If the same fraction were used in the sample 
dataset, there would be too few patients with the complication, making the dataset 
uninformative. Increasing the sample fraction of the complication creates richer 
information content in the dataset, but the resulting statistical model may be biased and 
inconsistent. Fortunately, theoretical analysis is possible to quantify the level of 
inconsistency and bias for most statistical models. The result can further guide the 
development of effective consistency and bias correction strategies. Because of the 
aforementioned advantages, statistical models can usually have a better prediction accuracy 
for complications than biological models. However, a major drawback of statistical models 
is that the results heavily depend on the particular dataset used in each study, so they may 
not generalize well.  
In this paper, we propose a general framework with specific methods for biological 
and statistical model integration in NTCP modeling. Our goal is to preserve the biological 
knowledge in NTCP modeling, and meanwhile use statistical modeling strategies to allow 
for inclusion of patient-specific variables and to better account for the special RT data 
characteristic. The integrated approach is expected to have better generalizability and 
predictive power than using biological and statistical models in separation.  
The contributions of this paper are two-folds: 
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• Novel model development: We propose the first-of-its-kind framework for 
biological and statistical model integration. Under the framework, we propose the 
details for developing the integrated model, including a novel model formulation, 
an efficient algorithm for parameter estimation, and theoretical analysis guided 
consistency and bias corrections to guarantee that the model has good statistical 
properties.  
• Real-data application: We apply the integrated model to a dataset of prostate cancer 
patients treated with Intensity Modulated RT (IMRT), an advanced type of RT, at 
Mayo Clinic Arizona. These patients are at risk of developing a serious 
complication called the grade 2+ acute rectal complication with symptoms 
including anal pain, diarrhea, and rectal obstruction. The integrated model achieves 
higher accuracy in predicting the complication compared with the statistical and 
biological models used in separation. Also, we perform extensive simulation 
studies on virtual patients whose data are sampled from the distribution of the real 
patients. Under various simulation settings, the integrated model outperforms the 
statistical and biological models in prediction accuracy due to the inclusion of 
patient-specific variables and in generalizability across different datasets due to the 
consideration of radiobiological principles.  
The rest of this paper is organized as follows: Section 2.2 presents the development of the 
integrated model; Section 2.3 presents the application and simulation studies. Section 2.4 
concludes the paper.  
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2.2 Integration of Biological and Statistical Models in NTCP Modeling 
We propose a model integration framework that includes three major steps: (i) One 
should start with an in-depth understanding of the biological model, especially the 
biological meanings of the model parameters. This guides the decision on which 
parameter(s) are appropriate to be personalized. (ii) Then, the selected biological model 
parameter(s) is linked with patient-specific variables in an appropriate way, producing an 
integrated model formulation. This formulation needs to be properly designed to account 
for the potential high-dimensionality of patient-specific variables and biological 
constraints on the model parameters. Under the formulation, an optimization algorithm is 
further developed to estimate the parameters of the integrated model, with considerations 
on optimality and efficiency. (iii) Finally, statistical properties of the integrated model, 
such as consistency and bias, are investigated, and corrections are made in order to produce 
consistent and unbiased estimators for the model parameters. In what follows, we present 
the details of the proposed approaches for accomplishing steps (i)-(iii) in sub-sections 
2.2.1- 2.2.3, respectively.  
2.2.1. Understanding the biological model in NTCP modeling 
The goal of NTCP modeling is to link the radiation dose delivered to a tissue of 
interest – a normal tissue to be spared from radiation toxicity – with the risk/probability of 
developing a complication. For each patient, the radiation dose distribution on the tissue 
volume can be extracted from the treatment planning software and represented by a Dose-
Volume-Histogram (DVH). Figure II.1 shows the DVH on rectum – the normal tissue of 
interest – for a prostate cancer patient receiving IMRT. There are two types of DVH. A 
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differential DVH plots the fraction of tissue volume receiving a specific amount of dose in 
the unit of Gray (Gy). A differential DVH takes the appearance of a typical histogram. A 
cumulative DVH uses the same x axis as a differential DVH but plots on the y axis the 
fraction of tissue volume receiving greater than or equal to a specific amount of dose.  
 
(a)                                                                              (b) 
Figure 2.1: (a) Cumulative DVH , and (b) differential DVH on rectum for a 
prostate cancer patient receiving IMRT 
In biological NTCP models, radiobiological principles are typically used to guide (i) the 
selection or development of a metric from DVH, which captures the essence of normal 
issue cells’ biological response to injury by ionizing radiation; and (ii) the determination 
of the functional form of the relationship between the metric and the probability of 
developing the complication. Next, we will present the details of a well-known biological 
NTCP model, called the LKB model (Gulliford et al., 2012). In the LKB model, a specific 
metric of DVH is used, called the generalized Equivalent Uniform Dose (gEUD), which 
takes the form of (II.1):  
𝑔𝐸𝑈𝐷 = (∑ 𝑣𝑖𝐷𝑖
1 𝑛⁄
𝑖 )
𝑛
 .                                                   (2.1) 
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𝑣𝑖 is the fractional tissue volume receiving a dose 𝐷𝑖 at the 𝑖-th DVH bin. 𝑣𝑖 and 𝐷𝑖 can be 
readily obtained from a given DVH. 𝑛 is a parameter of the LKB model, the meaning of 
which will be discussed later. It can be seen from (II.1) that 𝑔𝐸𝑈𝐷 collapses the complex 
dose distribution represented by a DVH into a single metric. The biological rationale 
behind this specific form of collapsing is that 𝑔𝐸𝑈𝐷 represents the uniform dose that, if 
delivered over the same number of fractions as the real but non-uniform dose distribution, 
yields the same radiobiological effect (Li et al., 2012).  Furthermore, the LKB model links 
𝑔𝐸𝑈𝐷 with the probability for a patient to develop the complication by a sigmoid-shape 
function, i.e.,  
𝑃(𝑌 = 1) = 𝜙 (
𝑔𝐸𝑈𝐷−𝑇𝐷50
𝑚 × 𝑇𝐷50
).                                                 (2.2) 
Here, 𝑌 is an indicator variable; 𝑌 = 1 represents that the patient has the complication and 
𝑌 = 0  otherwise. 𝜙(∙)  is the cumulative probability function for the standard normal 
distribution.  𝑇𝐷50  and 𝑚 are two other LKB model parameters. Figure II.2 shows the 
function of 𝑃(𝑌 = 1) with respect to 𝑔𝐸𝑈𝐷.  
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Figure 2.2: Probability of complication, 𝑃(𝑌 = 1), with respect to 𝑔𝐸𝑈𝐷 in LKB model 
Next, we will discuss the meanings of the three LKB model parameters, 𝑇𝐷50, 𝑚, and 𝑛. 
According to (2), 𝑇𝐷50  is the 𝑔𝐸𝑈𝐷  given to the normal tissue that results in 50% 
probability of the complication (Figure 2). Intuitively, 𝑇𝐷50  is the tolerance dose for 
developing the complication. That is, a slightly more 𝑔𝐸𝑈𝐷  than 𝑇𝐷50  will make the 
patient having a risk of developing the complication that is greater than a random guess. 
Furthermore, to understand parameter 𝑚, we take the partial derivative of  𝑃(𝑌 = 1) with 
respect to 𝑔𝐸𝑈𝐷 and evaluate this partial derivative at 𝑔𝐸𝑈𝐷 = 𝑇𝐷50, which gives:  
𝜕 𝑃(𝑌=1)
𝜕 𝑔𝐸𝑈𝐷
|
𝑔𝐸𝑈𝐷=𝑇𝐷50
=
1
√2𝜋
×
1
𝑚 × 𝑇𝐷50
.                                       (2.3) 
(II.3) means that 
1
√2𝜋
×
1
𝑚 × 𝑇𝐷50
 is the slope of the “𝑃(𝑌 = 1)  vs. 𝑔𝐸𝑈𝐷 ” curve at 
𝑔𝐸𝑈𝐷 = 𝑇𝐷50 (Figure II.2). The slope of this curve reflects sensitivity of the complication 
probability with respect to a change in 𝑔𝐸𝑈𝐷. The bigger the slope, i.e., the smaller the 
𝑚 × 𝑇𝐷50, the higher the sensitivity. Therefore, the meaning of 𝑚 is that it is inversely 
related to the sensitivity of the complication probability with a fixed 𝑇𝐷50. Finally, we 
discuss parameter 𝑛. In the LKB model, 𝑛 is constrained to be between 0 and 1. When 𝑛 =
1, it is obvious from (II.1) that 𝑔𝐸𝑈𝐷 becomes the average dose received by the normal 
tissue. When 𝑛 = 0, Proposition 1 shows that 𝑔𝐸𝑈𝐷 becomes the maximum dose received 
by the tissue (please see the proof in Appendix 1).  
Proposition 1: lim
𝑛→0
 𝑔𝐸𝑈𝐷 = lim
𝑛→0
(∑ 𝑣𝑖𝐷𝑖
1 𝑛⁄
𝑖 )
𝑛
= max
𝑖
𝐷𝑖.   
To obtain parameters of the LKB model in a particular clinical study, one needs a 
collection of patient data, based on which the parameters can be estimated by an Maximum 
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Likelihood Estimation (MLE). The LKB model has been extensively used to model various 
types of complications on many normal tissues/organs for major modern RT techniques. 
To consolidate the results from various studies, the American Association of Physicists in 
Medicine (AAPM) and the American Society for Radiation Oncology (ASTRO) jointly 
funded a multidisciplinary study, called Quantitative Analysis of Normal Tissue Effects in 
the Clinic (QUANTEC), in order to summarize the existing findings and develop clinical 
guidance. Reference values for the LKB model parameters were provided for clinically 
significant complications of 16 tissues/organs (Bentzen et al., 2010). 
2.2.2 Integration of patient-specific information into the biological model 
Formulation 
Based on the understanding of the LKB model parameters in the previous section, 
we now discuss which parameter(s) are more appropriate to be personalized.  According 
to the definition, 𝑇𝐷50 reflects the radiation dose a patient can tolerate before developing 
a complication with a chance higher than a random guess. Previous studies have shown 
that different patients have different tolerances depending on their age, health conditions, 
and even genetics (Boomsma et al., 2012; Cella et al., 2013). Therefore, it is obvious that 
𝑇𝐷50  should be to patient-specific. Furthermore, 𝑚 × 𝑇𝐷50   reflects the sensitivity of 
complication probability with respect to a change in radiation dose. There is no clear 
medical evidence so far to support whether or not this sensitivity should be patient-specific. 
Therefore, we choose not to personalize 𝑚 × 𝑇𝐷50. Finally, regarding parameter 𝑛, there 
is solid evidence in the literature to suggest that it is more organ-specific than patient-
specific (Gulliford et al., 2012; Li et al., 2012).  Specifically, in the RT literature, organs 
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are classified into parallel organs (e.g., lung, kidney, and liver) and serial organs (e.g., 
spinal cord, intestines, and optic nerves). Sub-units of a parallel organ function relatively 
independently, so radiation damage to a small region does not make the whole organ 
dysfunctional. Therefore, the probability of developing a complication for a parallel organ 
should be more related to the average dose it receives, i.e., with 𝑛 → 1. On the other hand, 
a serial organ tends to exhibit the complication if one subunit is incapacitated, so that the 
probability of developing a complication for a serial organ is more related to the maximum 
dose, i.e., with 𝑛 → 0.  
Due to these considerations, we propose to incorporate patient-specific variables 
into 𝑇𝐷50. Let 𝑥1𝑗, … , 𝑥𝑝𝑗 be 𝑝 patient-specific variables for patient 𝑗. Then,  
       𝑇𝐷50𝑗 = 𝛽0 +∑ 𝛽𝑘
𝑝
𝑘=1 𝑥𝑘𝑗,                                                          (2.4) 
where 𝛽0, 𝛽1, … , 𝛽𝑝 are parameters to be estimated. Also, because we have decided not to 
personalize the sensitivity, we can replace the 𝑚 × 𝑇𝐷50 in (II.2) by a new parameter 𝜎. 
Therefore, (II.2) becomes:  
            𝑃(𝑦𝑗 = 1) = 𝜙 (
𝑔𝐸𝑈𝐷𝑗(𝑛)−(𝛽0+∑ 𝛽𝑘
𝑝
𝑘=1 𝑥𝑘𝑗)
𝜎
).                                             (2.5) 
Let 𝛼𝑝+1 ≜ 𝜎
−1, 𝛼0 ≜ −𝛽0𝜎
−1, and 𝛼𝑘 ≜ −𝛽𝑘𝜎
−1. Then, (II.5) becomes: 
𝑃(𝑦𝑗 = 1) = 𝜙(𝛼0 +∑ 𝛼𝑘
𝑝
𝑘=1 𝑥𝑘𝑗 + 𝛼𝑝+1𝑔𝐸𝑈𝐷𝑗(𝑛)).                                   (2.6) 
Furthermore, using (II.6), the log-likelihood function can be written as 
𝑙(𝛼0, 𝛼1, … , 𝛼𝑝, 𝛼𝑝+1, 𝑛) = ∑ {𝑦𝑗𝑙𝑜𝑔𝑃(𝑦𝑗 = 1) + (1 − 𝑦𝑗)𝑙𝑜𝑔𝑃(𝑦𝑗 = 0)}𝑗 .                 
(2.7) 
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Note that there could be many patient-specific variables to be included in the model, 
resulting in too many parameters to be estimated. This runs a risk of overfitting, especially 
considering that the sample size in this type of studies is usually limited. Also, it is typical 
that only a few patient-specific variables out of the many are truly relevant to the 
development of a particular complication. Identification of these relevant variables has 
important clinical value. Because of these reasons, we propose to add a sparsity-inducing 
penalty like the 𝑙1 -penalty to (II.7). As a result, the parameters can be estimated by 
minimizing a 𝑙1-penalized negative log-likelihood function, i.e.,  
min
𝛼0,𝛼1,…,𝛼𝑝 ,𝛼𝑝+1,𝑛
{−𝑙(𝛼0, 𝛼1, … , 𝛼𝑝, 𝛼𝑝+1, 𝑛) + 𝜆 ∑ |𝛼𝑘|
𝑝
𝑘=1 }  
𝑠. 𝑡.   𝛼𝑝+1   ≥ 0                                                       (2.8) 
In (8), 𝜆 is a tuning parameter. Also note that we add a constraint that 𝛼𝑝+1 ≥ 0 to the 
optimization problem. This is to satisfy the biological validity that radiation dose always 
has a non-negative effect on the risk of developing a complication.  
Estimation 
The optimization problem in (2.8) is difficult to solve because of the complicated 
relationship between the objective function and the parameter 𝑛. On the other hand, with a 
fixed 𝑛, 𝑔𝐸𝑈𝐷𝑗(𝑛) can be computed from the DVH of each patient, and consequently (2.8) 
becomes a convex optimization with a linear constraint that is much easier to solve. This 
motivates us to treat 𝑛  as a tuning parameter rather than a parameter to be directly 
optimized. As a result, (2.8) can be written as (2.9):  
min
𝛼0,𝛼1,…,𝛼𝑝 ,𝛼𝑝+1
{−𝑙𝑛(𝛼0, 𝛼1, … , 𝛼𝑝, 𝛼𝑝+1) + 𝜆 ∑ |𝛼𝑘|
𝑝
𝑘=1 }  
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                                                                      𝑠. 𝑡.   𝛼𝑝+1   ≥ 0                                        (2.9) 
where both 𝑛  and 𝜆  are treated as tuning parameters. To solve (II.9), we propose an 
efficient algorithm based on the result of Proposition 2. The algorithm works by first 
solving the unconstrained optimization, which can be done by an efficient convex solver, 
and then using a simple fix to obtain the solution to the constrained optimization. Please 
see the proof of Proposition 2 in Appendix 2.  
Proposition 2: Let ?̂?0, … , ?̂?𝑝+1  be the solution to the optimization in (2.9).  Let 
𝛼0
∗ , … , 𝛼𝑝+1
∗  be the solution to unconstrained problem. If 𝛼𝑝+1
∗ ≥ 0, then (?̂?0, … , ?̂?𝑝+1) =
(𝛼0
∗ , … , 𝛼𝑝+1
∗ ). If 𝛼𝑝+1
∗ < 0, then (?̂?0, … , ?̂?𝑝) = (𝛼0
∗, … , 𝛼𝑝
∗) and ?̂?𝑝+1 = 0.  
Finally, we discuss how to choose the two tuning parameters. A grid search can be 
performed over all combinations of 𝑛 and 𝜆 values within their respective ranges. The 
optimal 𝑛∗ and 𝜆∗ are those that optimize a criterion. Commonly used criteria include BIC, 
AIC, and cross-validated deviance. The range of 𝜆, [𝜆𝑚𝑖𝑛 , 𝜆𝑚𝑎𝑥], is chosen such that 𝜆𝑚𝑎𝑥 
results in no patient-specific variables being selected (i.e., the sparsest model), and 𝜆𝑚𝑖𝑛 
results in all patient-specific variables or the number of patient-specific variables equal to 
the sample size being selected, whichever is smaller (i.e., the statistically plausible densest 
model). To set the range for 𝑛 , we can run the original LKB model and obtain the 
confidence interval for 𝑛. This confidence internal can be used as [𝑛𝑚𝑖𝑛 , 𝑛𝑚𝑎𝑥].  
2.2.3 Consistency and bias correction for the integrated model 
After the solution to (2.9), i.e., ?̂?0, … , ?̂?𝑝+1, is obtained, we will use the zero and non-zero 
patterns in ?̂?1, … , ?̂?𝑝 to select patient-specific variables. The selected variables will be used 
together with 𝑔𝐸𝑈𝐷𝑗(𝑛
∗) to fit a non-penalized model. This model can be used to predict 
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the probability of developing the complication for new patients. Let ?̃?0, … , ?̃?𝑞  denote the 
estimated coefficients from this non-penalized model by MLE, i.e.,  
              (?̃?0, … , ?̃?𝑞)= max
𝛼0,𝛼1,…,𝛼𝑞
𝑙𝑛∗(𝛼0, 𝛼1, … , 𝛼𝑞) 
                      = max
𝛼0 ,𝛼1,…,𝛼𝑞
∑ {𝑦𝑗𝑙𝑜𝑔𝑃𝑛∗(𝑦𝑗 = 1) + (1 − 𝑦𝑗)𝑙𝑜𝑔𝑃𝑛∗(𝑦𝑗 = 0)}𝑗 ,                 
(2.10) 
where 
𝑃𝑛∗(𝑦𝑗 = 1) = 𝜙(𝛼0 +∑ 𝛼𝑘
𝑞−1
𝑘=1 𝑥𝑘𝑗 + 𝛼𝑞𝑔𝐸𝑈𝐷𝑗(𝑛
∗)).                        (2.11) 
The form of (2.11) is known as the probit model. The reason of re-fitting a non-
penalized model is that the 𝑙1-penalty is known to have a shrinking effect, which makes an 
𝑙1-penalized model a good variable selection model but not necessarily a good predictive 
model (Hastie et al., 2015). Next, we discuss two important statistical properties of the 
estimators ?̃?0, … , ?̃?𝑞, i.e., consistency and bias. In statistics, a consistent estimator is one 
that converges in probability to the true value of the parameter being estimated as the 
sample size goes to infinity. The bias of an estimator is the difference between the 
estimator’s expected value and the true value of the parameter being estimated. If the bias 
is zero, the corresponding estimator is called an unbiased estimator. A good estimator 
should be consistent and unbiased.  
Consistency 
The population of patients going through a RT is typically heavy imbalanced, i.e., 
a very small fraction of the population will develop the complication of interest while the 
large majority will not. Otherwise, the RT would not have been permitted for practice. 
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When a dataset is sampled from the population for NTCP modeling, a common strategy is 
to include a larger fraction of patients with the complication in the dataset than what this 
faction truly is in the population. This is to make sure that the dataset has enough samples 
with 𝑌 = 1 (i.e., with the complication) and thus rendering a meaningful statistical analysis 
(King and Zeng, 2001). However, when this sampling strategy is used, ?̃?0  is not a 
statistically consistent estimator for 𝛼0 , although ?̃?1, … , ?̃?𝑞  still are. This finding is 
summarized in Proposition 3. 
Proposition 3: Let 𝜏 and ?̅? be the fractions of patients with 𝑌 = 1 in the population and in 
the sample dataset, respectively. If ?̅? ≠ 𝜏, then ?̃?0 is not a consistent estimator for 𝛼0 while 
?̃?1, … , ?̃?𝑞 are consistent estimators for 𝛼1, … , 𝛼𝑞.  
To produce a consistent estimator, we propose a maximum weighted likelihood 
estimation (MWLE) to estimate the non-penalized model in (II.11). In the MWLE, the log-
likelihood function takes a weighted form, i.e.,  
𝑙𝑛∗
𝑤 (𝛼0, 𝛼1, … , 𝛼𝑞) = 𝑤1 ∑ log𝑃𝑛∗(𝑦𝑗 = 1){𝑦𝑗=1} + 𝑤0 ∑ log𝑃𝑛∗(𝑦𝑗 = 0){𝑦𝑗=0} ,      
(2.12) 
where 𝑤1 = 𝜏 ?̅?⁄ , 𝑤0 = (1 − 𝜏) (1 − ?̅?)⁄ . By maximizing (2.12), we can obtain estimates 
for 𝛼0, 𝛼1, … , 𝛼𝑞 , denoted by ?̌?0, … , ?̌?𝑞. Proposition 4 shows that ?̌?0, … , ?̌?𝑞  are consistent 
estimators. Proofs of Propositions 3 and 4 share a similar idea to the proof of consistency 
for the weighted exogenous sampling maximum likelihood (WESML) estimator in Manski 
and Lerman, 1977, and thus skipped here due to space limit.  
Proposition 4: ?̌?0, … , ?̌?𝑞 are consistent estimators for 𝛼0, 𝛼1, … , 𝛼𝑞.  
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Note that the weighted log-likelihood function proposed in (2.12) assumes a known 
𝜏. 𝜏 is straightforward to obtain. For example, it can be estimated from a data source that 
only records patients’ complications, such as the Electronic Health Records. Because such 
a data source does not include the RT dose, it can be easily created and thus including a 
large patient population to grant an accurate estimate for 𝜏. 𝜏 may also be obtained from 
published epidemiologic studies on the RT, which usually report the fraction of people 
developing the complication in a large population.  
Bias 
Although ?̌?0, … , ?̌?𝑞 are consistent estimators, they are still biased. Proposition 5 
derives the bias of these estimators. Please see the proof in Appendix 3.  
Proposition 5: Let ?̌? = (?̌?0, … , ?̌?𝑞). Denote the true values of the parameters being 
estimated by 𝛂 = (𝛼0, … , 𝛼𝑞). The bias of ?̌? is 
𝑏𝑖𝑎𝑠(?̌?) = 𝐸(?̌?) − 𝛂 = (𝐗𝑇𝐖𝐗)−1𝐗𝑇𝐖𝛏.                                    (2.13) 
𝐗 is the 𝑁 × (𝑞 + 1) data matrix of all the predictors including the intercept. 𝐖 is an 
𝑁 × 𝑁 diagonal matrix with the 𝑗-th diagonal element being 
𝐖𝑗𝑗 =
𝑤0𝜙(𝜂𝑗)+𝑤1(1−𝜙(𝜂𝑗))
𝜙(𝜂𝑗)(1−𝜙(𝜂𝑗))
𝜑2(𝜂𝑗), 
where 𝜂𝑗 = 𝛼0 +∑ 𝛼𝑘
𝑞−1
𝑘=1 𝑥𝑘𝑗 + 𝛼𝑞𝑔𝐸𝑈𝐷𝑗(𝑛
∗) and 𝜑(∙) is the standard normal 
probability density function. 𝛏 is a 𝑁 × 1 vector with the 𝑗-th element 𝜉𝑗 being 
𝜉𝑖 =
𝜂𝑗𝜙(𝜂𝑗)−(𝑤1−1)𝜑(𝜂𝑗)
2𝜙(𝜂𝑗)
𝐐𝑗𝑗,  
where 𝐐𝑗𝑗 is the 𝑗-th diagonal element of matrix 𝐐 = 𝐗(𝐗
𝑇𝐖𝐗)−1𝐗𝑇. 
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Using the result in Proposition 5, we can obtain an unbiased estimator for 𝛂, i.e., ?̈? = ?̌? −
𝑏𝑖𝑎𝑠̈ (?̌?). 𝑏𝑖𝑎𝑠̈ (?̌?) is an estimate for the theoretical bias in (2.13) by using ?̌?𝑗 = ?̌?0 +
∑ ?̌?𝑘
𝑞−1
𝑘=1 𝑥𝑘𝑗 + ?̌?𝑞𝑔𝐸𝑈𝐷𝑗(𝑛
∗) . Furthermore, it can be shown that 𝑉𝑎𝑟(?̈?) =
(
𝑁−𝑞−1
𝑁
)
2
𝑉𝑎𝑟(?̌?). Given that the sample size 𝑁 is typically larger than the number of 
parameters, 𝑞 + 1, we can get 𝑉𝑎𝑟(?̈?) < 𝑉𝑎𝑟(?̌?). This means that the variance of ?̈? is 
smaller than ?̌?, i.e., the bias correction does not increase the variance of the estimator. 
Proof for the above variance relationship is similar to that for the case of generalized linear 
models (Cordeiro and McCullagh, 1991).  
Finally, we summarize the steps of our proposed integrated model, as introduced in 
Sections 2.2.2 and 2.2.3, in Figure 2.3. The R code of our model has been submitted to 
GitHub website and is publicly available at https://github.com/xliu203/Integration-of-
biological-model-and-statistical-model/blob/master/glmnet.probit_v2.R. 
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Figure 2.3: A flow chart of the steps for the proposed integrated model 
2.3 Case Study  
2.3.1 Application to NTCP modeling of acute rectal complication for IMRT treatment of 
prostate cancer  
 
We present an application in which patients were treated with IMRT for prostate 
cancer. A serious complication these patients may suffer from after the IMRT is the grade 
2+ acute rectal complication with symptoms including anal pain, diarrhea, and rectal 
obstruction. We obtain a dataset of 86 patients from our collaborative institution, 
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Department of Radiation Oncology at Mayo Clinic Arizona. The study was approved by 
the Institutional Review Board (IRB) of Mayo Clinic Arizona and included written 
informed consent from all subjects. All patients were diagnosed with prostate cancer. The 
IMRT they received was set up using the following protocol: A static field IMRT technique 
with 7 coplanar 6MV fields was employed. The whole prostate was designated as a Clinical 
Target Volume (CTV), and two Planning Target Volumes (PTVs) were created using 
uniform 3mm and 6mm expansions. A dose of 77.4 Gy in 43 fractions (1.8Gy/fraction) 
was prescribed to the 3mm expansion, and a dose of 70 Gy to the 6mm expansion. Seminal 
Vesicles with uniform 7mm expansion were prescribed 54 Gy. A simultaneous integrated 
boost (SIB) was given to areas suspicious for cancer as demonstrated in a planning multi-
parametric magnetic resonance scan which was a combination of T2-weighted imaging, 
Diffusion Weighted Imaging and Dynamic Contrast-Enhanced imaging. The SIB volume 
was identified by a diagnostic radiologist specializing in genitourinary imaging, was not 
expanded, and was prescribed 81-83Gy. All patients were planned using the Eclipse 
Treatment Planning System (TPS) produced by Varian, Inc. 
Because we focus on the rectal complication, the rectum was drawn as a whole 
organ bounded by ischial tuberosity inferiorly and sigmoid flexure superiorly. Then, DVH 
on the rectum was extracted for each patient using automated scripts which were written 
within the Applications Programmer Interface (API) of the Eclipse TPS manufactured by 
Varian, Inc. Furthermore, we include 11 patient-specific variables that potentially affect 
the complication, which are age, concurrent treatment status, diabetes status, Gleason score, 
Androgen Deprivation Therapy (ADT) status, adjuvant ADT status, neoadjuvant ADT 
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status, prostate-specific antigen (PSA) level prior to treatment, prostate volume, use of 
statin medications, and stage of the disease (T-stage).  After the IMRT, each patient’s 
medical records were reviewed by a physician and his rectal complication was graded 
according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 
Among the 86 patients in the dataset, 23 developed the grade 2+ acute rectal complication. 
We apply the integrated model to the dataset according to the steps in Figure 3. Recall that 
the integrated model includes a step for consistency correction in case that the population 
fraction of complication, 𝜏, is smaller than the sample fraction of complication, ?̅?. In our 
dataset, ?̅? =
23
86
= 26.7% , while 𝜏 < 20% in the published literature on population-based 
studies (Tucker et al., 2012). Therefore, consistency correction is needed. Furthermore, to 
choose the optimal tuning parameters, we adopt a model selection criterion called AICc, 
which includes a correction for the original AIC under small sample sizes (Hurvich and 
Tsai, 1989). The results from the integrated model are as follows: Among all the patient-
specific variables included in the dataset, six are selected using AICc: diabetes status, 
prostate volume, PSA, statins use, ADT status, T-stage. The optimal 𝑛∗ is found to be 0.154. 
These results are consistent with findings in the literature. For example, statins are a class 
of drugs often prescribed by doctors to help lower cholesterol levels in the blood. Statins 
use is negatively related to the probability of complication, indicating that the use of statins 
might be protective against the development of the 2+ acute rectal complication for patients. 
At least one biological mechanism behind this seemingly protective effect has been 
suggested (Malek, 2015), and a relatively recent study reported a similar result, namely a 
negative association between acute rectal complication during pelvic RT and the use of 
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statins (Wedlake et al., 2012). This corroborates our finding. PSA is a blood test that is 
commonly used to detect prostate cancer; the higher level of PSA, the higher chance the 
patient has prostate cancer. Finally, knowing that the range of 𝑛 is between 0 and 1, the 
optimal 𝑛∗ = 0.154 found by the integrated model is small. This is consistent with prior 
findings (Bentzen et al., 2010) and agrees with the clinical expectation that because rectum 
is a serial organ, it is well-known that serial organs tend to have small 𝑛 (Gulliford et al., 
2012; Li et al., 2012). 
Furthermore, we would like to assess the prediction/classification accuracy of the 
integrated model in comparison with the biological and statistical models used alone. The 
best strategy in accuracy assessment of a statistical model without running the risk of 
overfitting is to divide the entire dataset into a training set and a test set. Samples in the 
test set are not used in training but only used to compute the classification accuracy of the 
training model. Realizing that we have a small dataset, we put all but one samples in the 
training set and the remaining sample in the test set. This will allow us to compute the 
classification accuracy on one test sample. We repeat this training-test split over all the 
samples, which will allow us to compute the test accuracy on all samples. Note that this 
scheme is different from leave-one-out cross validation, because the latter would report the 
best accuracy optimized on the test set while our scheme assumes the test set is completely 
unseen at the training stage. Using this scheme, Table 1 show the test accuracy of the 
integrated model in comparison with those of the biological and statistical models. The 
accuracy metric is Area Under the Curve (AUC). Use of AUC avoids having to choose a 
cutoff for the predicted probabilities and therefore provides a more objective measure for 
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the prediction accuracy. Recall that LKB model fitting only uses the DVH and cannot take 
patient-specific variables into consideration. As a result, the AUC is low. The commonly 
used statistical model in the NTCP literature is logistic regression (Cella et al., 2013; 
Boomsma et al., 2012; Deville et al., 2012). We follow the convention of NTCP modeling 
and build a logistic regression that includes  𝐷10% ,  𝐷15% ,  𝐷20% , ⋯ ,  𝐷90%  and patient-
specific variables as predictors. Here, 𝐷𝛼% is the radiation dose such that 𝛼% of the rectal 
volume receives this dose level or higher. For a fair comparison with the integrated model, 
we also use an 𝑙1-penalty for variable selection and select the penalty parameter using AICc. 
The AUC of the statistical model is around 0.76, which is also lower than the integrated 
model.   
Table 2.1:  Comparison between the AUCs of the integrated model, biological 
model (LKB), and statistical model (𝑙1-penalized logistic regression)  
 Integrated model Biological model Statistical model 
AUC on test data 0.82 0.66 0.76 
 
Finally, we report the AUCs of the integrated model under other model selection criteria. 
The AUCs under AIC and BIC are 0.82 and 0.78, respectively, which are still higher than 
the biological and statistical models used alone. The AUC under AIC is the same as that 
under AICc (Table II.1), implying that the integrated model is not sensitive to small sample 
correction that is accounted for by AICc. The AUC under BIC is relatively lower than other 
criteria. BIC has been known to most suitable for cases when there is a very large number 
of predictors, while our study involves only 11 predictors.  
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2.3.2 Simulation experiments 
We would like to compare the performance of the integrated model with biological 
and statistical models under different parameter settings using simulation data. A 
significant challenge of this study is how to simulate DVH for each virtual patient. To make 
sure that the simulated DVH has similar data characteristics to the DVH of real patients, 
we simulate the DVH of each virtual patient from the DVH measurements of the 86 real 
patients. Specifically, we fit a multivariate normal distribution for a random vector 
of (𝐷1%, 𝐷2%, … , 𝐷99%)
𝑇 using the DVH of the 86 patients. Next, we sample from the fitted 
distribution to create the DVH for a virtual patient. Then, the DVH is used to compute 
𝑔𝐸𝑈𝐷(𝑛) using (1). We set 𝑛 = 0.2 and 0.3 in our simulation experiments. Furthermore, 
we sample from a multivariate normal distribution, (𝑋1, … , 𝑋𝑝)
𝑇
~𝑁𝑝(𝟎, 𝚺), to create data 
for 𝑝 patient-specific variables of the virtual patient. 𝚺 has all the diagonal elements being 
one and off-diagonal elements being 𝚺𝑖𝑗 = 0.2
|𝑖−𝑗|  to account for possible correlation 
between the variables. We set 𝑝 = 14 in our experiment, which is close to the number of 
patient-specific variables included in the real-data application in Section II.3.1.  
Furthermore, to set the coefficients for the patient-specific variables and 𝑔𝐸𝑈𝐷(𝑛), 
we refer to the model in (II.14) for proper ranges of the coefficients. 10 out of the 14 
patient-specific variables are set to have zero coefficients. In this way, we can test the 
accuracy of the model in selecting patient-specific variables. In the remaining four patient-
specific variables with non-zero coefficients, two are set to have positive coefficients and 
the other two are set to have negative coefficients. The magnitude of non-zero coefficients 
is set to be |𝛼𝑘| = 0.8, 𝑘 = 1,2,3,4. We also run experiments on a smaller magnitude of 
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0.6. The coefficient for 𝑔𝐸𝑈𝐷(𝑛) is set to be 𝛼𝑝+1 = 0.25 and 0.3. The intercept 𝛼0 is set 
to achieve a desired population fraction of complication, 𝜏 .  𝜏 = 20% is used in our 
experiments.  
With simulated data for a virtual patient and under a particular setting of the model 
coefficients, we use the right-hand side of (II.6) to generate the probability that the patient 
develops the complication. Then, this probability is used as the parameter of a Bernoulli 
distribution from which a binary variable 𝑦 can be sampled. Furthermore, to mimic the 
reality that the sample fraction of complication in a dataset, ?̅?, is usually higher than the 
population fraction of complication, 𝜏, we set ?̅? = 40%. The sample size of the dataset is 
200.  
We apply the integrated model, LKB, and 𝑙1-penalized logistic regression to the 
simulation datasets. The results are shown in Tables II.2-5. The following observations can 
be drawn:  
Table 2.2: Comparison between the integrated model, biological model, and 
statistical model (|𝛼𝑘| = 0.8, 𝛼𝑝+1 = 0.25, 𝑛 = 0.2). Mean (standard deviation) and 
confidence interval are computed based on 50 repetitions of the simulation experiment.  
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p<0.001* is the p value for a one-sided hypothesis testing that the integrated model has a 
higher LOOCV-AUC than the biological or statistical model whichever has a higher 
LOOCV-AUC.  
Table 2.3: Comparison between the integrated model, biological model, and 
statistical model (|𝛼𝑘| = 0.6, 𝛼𝑝+1 = 0.25, 𝑛 = 0.2). Mean (standard deviation) and 
confidence interval are computed based on 50 repetitions of the simulation experiment. 
 
p<0.001* is the p value for a one-sided hypothesis testing that the integrated model has a 
higher LOOCV-AUC than the biological or statistical model whichever has a higher 
LOOCV-AUC.  
Table 2.4: Comparison between the integrated model, biological model, and 
statistical model (|𝛼𝑘| = 0.8, 𝛼𝑝+1 = 0.3, 𝑛 = 0.3). Mean (standard deviation) and 
confidence interval are computed based on 50 repetitions of the simulation experiment. 
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p<0.001* is the p value for a one-sided hypothesis testing that the integrated model has a 
higher LOOCV-AUC than the biological or statistical model whichever has a higher 
LOOCV-AUC.  
Table 2.5: Comparison between the integrated model, biological model, and 
statistical model (|𝛼𝑘| = 0.6, 𝛼𝑝+1 = 0.3, 𝑛 = 0.3). Mean (standard deviation) and 
confidence interval are computed based on 50 repetitions of the simulation experiment. 
  
p<0.001* is the p value for a one-sided hypothesis testing that the integrated model has a 
higher LOOCV-AUC than the biological or statistical model whichever has a higher 
LOOCV-AUC.  
 
First, the LOOCV-AUC of the integrated model is significantly higher than LKB and 
logistic regression (p value <0.001) across all the simulation settings. The LOOCV-AUC 
of the integrated model becomes lower when the magnitude of coefficients for patient-
specific variables, |𝛼𝑘|, gets smaller, but it is little affected by 𝑛 and the coefficient for 
𝑔𝐸𝑈𝐷(𝑛), 𝛼𝑝+1. Moreover, although LKB has the lowest mean LOOCV-AUC among the 
three models, the standard deviation of the LOOCV-AUC over 50 repetitions of the 
simulation experiment for LKB is the smallest. This is expected because LKB, as a 
biological model, is built upon radiobiological principles such that its performance is less 
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affected by sampling variability. On the other hand, logistic regression has the largest 
standard deviation of the LOOCV-AUC. This is because statistical models are pure data-
driven and therefore the performance is more variable across different datasets. By 
integrating the biological and statistical models, the proposed integrated model can achieve 
a high accuracy due to the inclusion of patient-specific variables and a more robust 
performance against sampling variability due to the consideration of radiobiological 
principles. 
Furthermore, the integrated model achieves high sensitivity and specificity in selecting the 
patient-specific variables across all the experiments. Here, sensitivity is the proportion of 
non-zero coefficients for patient-specific variables that are correctly identified as non-zero. 
Specificity is the proportion of zero coefficients for patient-specific variables that are 
correctly identified as zero. The sensitivity and specificity becomes lower when the 
magnitude of coefficients for patient-specific variables, |𝛼𝑘| , gets smaller. The same 
phenomenon is observed when we keep |𝛼𝑘| unchanged but decrease the sample size. 
These observations are consistent with the findings of existing variable selection 
approaches (Huang et al., 2012). Logistic regression achieves a similar level of sensitivity 
and specificity to the integrated model. Considering this result together with that on AUC, 
we can conclude that logistic regression may perform as well as the integrated model on a 
single dataset, which is reflected by the sensitivity and specificity in selecting patient-
specific variables. However, it performs worse than the integrated model when one wants 
to apply the model trained on one dataset to another dataset (i.e., weaker generalizability), 
which is reflected by the AUC. 
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Finally, we compare the estimated parameter 𝑛 between the integrated model and LKB. A 
universally true observation across all the experiments is that the confidence interval of 𝑛 
includes the true value in the integrated model but not in LKB. Because LKB fails to 
account for the effect of patient-specific variables on the probability of complication, its 
parameter estimation is compromised. This result corroborates the low LOOCV-AUC of 
LKB.  
2.4 Conclusion 
In this paper, we proposed an integrated model for NTCP modeling. We developed the 
model by starting with an in-depth understanding of the biological model (i.e., LKB) 
parameters. Among all the parameters, 𝑇𝐷50  reflects the radiation dose a patient can 
tolerate before developing complication with a chance higher than a random guess, and 
therefore should be patient-specific. We proposed to link patient-specific variables with 
𝑇𝐷50 by a linear model and used this personalized  𝑇𝐷50 to replace the original 𝑇𝐷50 in 
LKB. This resulted in an integrated model formulation. We further added to the 
formulation a sparsity-inducing penalty to enable variable selection from high-dimensional 
patient-specific variables, and a biological constraint on the model coefficients to account 
for the fact that radiation dose always poses at least “some” risk of complication to the 
normal tissue. Next, we developed an efficient algorithm to estimate the parameters of the 
integrated model. Furthermore, we performed theoretical analysis and proposed modified 
approaches to ensure that the integrated model have statistical consistent and unbiased 
coefficient estimators. Finally, we applied the integrated model to a real dataset of prostate 
cancer patients treated with IMRT who are at risk of developing the grade 2+ acute rectal 
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complication. The integrated model had higher prediction accuracy measured by LOOCV-
AUC than the biological (i.e., LKB) and statistical models (i.e., 𝑙1 -penalized logistic 
regression) used in separation. Also, three patient-specific variables were selected by the 
integrated model as important predictors to the complication, including age, statins use, 
and PSA. Age and statins use have also been found to be related to the risk of complication 
in the existing RT literature. The finding about PSA was novel and further investigation on 
the biological mechanism is yet to be performed. Various simulation studies were also 
conducted, showing that the integrated model significantly outperformed both biological 
and statistical models in LOOCV-AUC. The variable selection sensitivity and specificity 
of the integrated and statistical models were comparable. These results indicated that the 
statistical model may perform as well as the integrated model on a single dataset, but it has 
worse generalizability to other studies. In addition, the integrated model accurately 
estimated the organ parameter 𝑛 while LKB was not able to.  
There are some limitations of the present study, which drive future investigation: The 
proposed model was demonstrated on a small dataset consisting of 86 patients with 23 
individuals having complications. More data are needed to further validate the model and 
findings. Also, our study found PSA to be a significant predictor for rectal complication of 
prostate cancer patients. We are not aware of any prior study that reported this relationship, 
although there are plenty of studies that correlate PSA with the existence of prostate cancer 
(Partin et al., 1996; Catalona et al., 2000; Catalona et al., 1997). Further investigation is 
needed to validate this finding with more data and discover the biological mechanism 
behind this relationship if still held true.  
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CHAPTER 3 
A TRANSFER LEARNING MODEL FOR MULTI-MODALITY IMAGE DATA 
FUSION WITH APPLICATION IN ALZHEIMER’S DISEASE EARLY DETECTION 
 
3.1 Introduction 
Multimodality datasets are becoming increasingly common in various domains to 
provide complementary information for predictive analytics. For example, in health care, 
images of different types such as structural magnetic resonance imaging (MRI) and 
fludeoxyglucose positron emission tomography (FDG-PET) provide complementary 
information about the organ of interest, which allows for building a predictive model to 
accurately detect a certain disease (Jack et al. 2009; Lowe et al. 2009; Clark et al. 2011). 
In manufacturing, data collected from multiple different types of sensors provide 
complementary information about the process and product, allowing for more accurate 
assessment of process and product quality (Basir and Yuan 2007).  
One important challenge for integration of multimodality datasets in building a 
predictive model is that the multiple different modalities are not universally available for 
all the samples. Take the diagnosis of the Alzheimer’s disease (AD) – a fatal neurological 
disorder – using multimodality images as an example. Figure 1 shows the special 
“incomplete multimodality dataset (IMD)” we are focusing on in this paper, which includes 
three complementary diagnostic image modalities, i.e., MRI, FDG-PET, and amyloid-PET 
for detection of AD at an early stage of the disease called Mild Cognitive Impairment (MCI) 
(Jack et al. 2012). In the recently published expert consensus criteria by the National 
Institute of Aging and Alzheimer’s Association, the use of multimodality images for early 
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detection of AD has been highly recommended (Albert et al. 2011). In Figure III.1, each 
sub-cohort consists of patients who have the same availability of modalities. Different sub-
cohorts have different missing modality patterns. The reasons for the existence of IMD are 
multifold: some imaging equipment such as PET is costly and only available in limited 
clinics; some modalities are not accessible to patients due to insurance coverage; it is not 
safe to put patients with some pre-existing conditions through a certain imaging 
examination.  
 
Figure 3.1.  An example of the incomplete multimodality dataset (IMD), in which MRI, 
FDG-PET, and amyloid-PET are considered as three modalities. Columns within each 
modality represent features extracted from the image. Each sub-cohort consists of 
patients with the same availability of modalities.  
If we applied existing methods to model IMD, there would be three options.  
1) Missing data imputation followed by a statistical model that uses imputed features to 
predict a response variable of interest. While there are many imputation algorithms 
(He et al. 2017; Beaulieu-Jones, Moore, and CONSORTIUM 2017; Ordóñez Galán et 
al. 2017), they are not suitable for use to fill in the missing data in IMD because of 
several reasons. First, as seen in the example in Fig. 1, there is a substantial amount of 
missing data in IMD. Imputation will result in a dataset with poor quality. Second, 
MRI FDG-PET Amyloid-PET
Sub-cohort 4
Sub-cohort 3
Sub-cohort 2
Sub-cohort 1
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data in IMD are missed as the entire modality/modalities, which violates the 
fundamental missing-at-random assumption that most imputation algorithms have to 
assume.  
2) Separate modeling (SM). This approach would build a separate predictive model for 
each sub-cohort, e.g., four separate models for the dataset in Figure III.1. The 
limitation of SM is obvious: because each model can only use the data specific to the 
corresponding sub-cohort, sample size shortage may prevent building a robust model.  
3) All available data modeling (AADM). This approach would build four models for 
the dataset in Figure III.1: an MRI-alone model using the data in all sub-cohorts; an 
MRI & FDG-PET model using the data in sub-cohorts 2 and 3; an MRI & amyloid-
PET model using sub-cohorts 3 and 4; an MRI & FDG-PET & amyloid-PET model 
using sub-cohort 3. AADM requires data pooling from different sub-cohorts which 
typically contain patients from different institutions. This is practically difficult, if not 
impossible, due to the need for multi-institutional collaboration agreement and patient 
privacy concerns.  
In this paper, we propose a novel Incomplete-Multimodality Transfer Learning 
(IMTL) model to tackle the aforementioned limitations of existing methods. Different from 
missing data imputation, IMTL does not fill in missing data but utilize whatever data that 
is available to build a predictive model for each sub-cohort. Different from SM and AADM, 
IMTL estimates the sub-cohort-specific models jointly rather than in separation. In this 
way, knowledge obtained from the modeling of each sub-cohort can be “transferred” to 
help the modeling of other sub-cohorts. This makes IMTL a transfer learning model. Also, 
37 
 
the model estimation of IMTL does not require data pooling from different sub-cohorts 
like AADM. We propose a computational architecture that that includes iterative 
communication between global and local learners to allow for between-institutional 
collaborative model estimation without the need for data pooling. This is particularly 
important for patient privacy preservation in health care applications of IMTL. Finally, we 
would like to stress that although IMTL is developed in the context of multimodality data 
in health care, it can be effortlessly extended to other non-medical domains that fusion of 
multimodality datasets is common and much needed, including but not limited to 
manufacturing (Basir and Yuan 2007) and transportation (Xia, Li, and Shan 2013).  
The remainder of the paper is organized as follows: Section 3.2 provides a literature 
review. Section 3.3 presents the development of IMTL. Section 3.4 investigates unique 
properties of IMTL. Section 3.5 presents case studies. Section 3.6 is the conclusion. 
3.2 Literature Review 
This paper primarily intersects with the research area of statistical and machine 
learning models using data missed in chunks of modalities, termed as IMD in this paper. 
To our best knowledge, this area only has limited work. In what follows, we review each 
related paper in detail.  
Yuan et al. (2012) proposed an incomplete multisource feature learning method 
(iMSF), which used an 𝑙21 penalty to enforce same features within each modality to be 
selected across different sub-cohorts. One limitation of iMSF is that it cannot do “out-of-
sample prediction”. That is, if a modality-wise missing pattern is not included in training 
data, iMSF cannot make a prediction on new samples with that missing pattern. Also, the 
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𝑙21 enabled feature selection scheme is most effective if different modalities have little 
correlation. To overcome the limitations of iMSF, Xiang et al. (2014) proposed an 
incomplete source-feature selection (ISFS) model. The main idea was to estimate a set of 
common coefficients across different sub-cohorts and specific coefficients to account for 
the uniqueness of each sub-cohort. To gain this flexibility, ISFS needs to estimate many 
parameters.      
Thung et al. (2014) developed a matrix completion method, which selected samples 
and features in the original dataset to produce a smaller dataset. This was done by using 
the group-lasso based multitask learning algorithm twice on features and samples, 
respectively. Then, standard missing data imputation algorithms were applied to the 
reduced dataset and classifiers were built on the imputed data. While the proposed idea of 
data reduction is novel, imputation would still have to be used.  
Liu et al. (2017) proposed a view-aligned hypergraph learning (VAHL) method. 
VAHL divided the dataset into several views according to the availability of different 
modalities. A hypergraph of subjects was constructed on each view. Then, the hypergraphs 
were fused by a view-aligned regularizer under a classification framework. VAHL had a 
novel perspective of exploiting subject relationship using hypergraphs to naturally get 
around the issue of missing modalities. Also because of this “subject” perspective, the 
model has to be re-trained from scratch every time new data are becoming available. Also, 
VAHL has many parameters to estimate. 
Li et al. (2014) proposed a deep learning (DL) framework specifically for imaging 
data. The basic idea was to train a 3-D convolutional neutral network (CNN) between two 
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imaging modalities, MRI and FDG-PET, based on a dataset in which both modalities were 
available. The CNN was then used to predict a “pseudo” PET from an MRI image for any 
patient whose PET is missing. This work represents one of the pioneers that introduced DL 
into imaging-based AD diagnosis and prognosis. On the other hand, DL models are black-
box models with difficulty for interpretation. Also, while crafting pseudo PET from MRI 
is possible from a pure data-driven perspective, the idea needs further validation by 
imaging physics.  
In summary, limited work has been done to develop statistical models for IMD data. 
All the above-reviewed models, despite their specific weakness, share some common 
limitations: 1) Most models cannot do out-of-sample prediction, which limits broader 
utilization; 2) Model estimation needs data pooling from different sub-cohorts. If the sub-
cohorts correspond to different health institutions, which is typically the case, protection 
of patient privacy is a concern. Also, the institutions have to establish data sharing 
agreement before the modeling can take place, which is a lengthy process if not impossible. 
3) While showing empirically good performance on specific datasets, there is a lack of 
theoretical study on why the performance is guaranteed.  
3.3 Development of the Incomplete-Multimodality Transfer Learning (IMTL) Model 
For notation simplicity, we present our model development in the context of three 
modalities, while the model is easily generalizable to any number of modalities. For 
example, the three modalities can be MRI, FDG-PET and amyloid-PET as shown in Figure 
3.1. Under this structure, there are four patient sub-cohorts corresponding to different 
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availabilities of the modalities: 1) MRI alone; 2) MRI & FDG-PET; 3) MRI & amyloid-
PET; 4) all three modalities.  
Let 𝑘 be the index for modalities, 𝑘 = 1,2,3; 𝑙 be the index for sub-cohorts, 𝑙 =
1,2,3,4; and 𝑖 be the index for samples/patients, 𝑖 = 1, … , 𝑛. Denote the sample size of each 
sub-cohort by 𝑛𝑙. Let 𝐱𝑖
(𝑘𝑙)
 contain features in modality 𝑘 for patient 𝑖 in sub-cohort 𝑙. Let 
𝑦𝑖
(𝑙)
 be the response variable (e.g., a diagnostic or prognostic result) for patient 𝑖 in sub-
cohort 𝑙. We propose two IMTL models, one for a continuous response variable (i.e., a 
predictive model) and the other for a binary response variable (i.e., a classification model). 
3.3.1. IMTL predictive modeling 
1) Formulation and estimation  
Consider the joint distribution of 𝑦𝑖
(𝑙)
, 𝐱𝑖
(2𝑙)
, and  𝐱𝑖
(3𝑙)
 given 𝐱𝑖
(1𝑙)
 to be 
multivariate normal, i.e.,  
(𝑦𝑖
(𝑙), 𝐱𝑖
(2𝑙) , 𝐱𝑖
(3𝑙)) | 𝐱𝑖
(1𝑙) ∼ 𝑀𝑉𝑁 (𝛍(𝐱𝑖
(1𝑙)) ,    𝚺).                                   (3.1) 
Here, we consider features in modality 1, 𝐱𝑖
(1𝑙)
, to be covariates instead of random variables 
because 𝐱𝑖
(1𝑙)
 contains no missing features. Making it covariates does not affect the 
performance of IMTL and meanwhile has the benefit of reducing the number of parameters 
to be estimated.  
In (3.1), 𝛍(∙) is a vector function of covariates. Although 𝛍(∙) can take any form in theory, 
we focus on a linear function in this paper, i.e.,  
𝛍(𝐱𝑖
(1𝑙)) = (𝐱𝑖
(1𝑙)𝛃1 + 𝛽0, 𝐱𝑖
(1𝑙)𝐀2 + 𝐛2, 𝐱𝑖
(1𝑙)𝐀3 + 𝐛3),                            (3.2) 
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where 𝛃1, 𝛽0, 𝐀2, 𝐛2, 𝐀3, 𝐛3 are coefficients. The conditional covariance matrix 𝚺 in (III.1) 
can be written in a more explicit format to include sub-matrices of covariance between the 
response and each modality and between the modalities, i.e.,  
𝚺 = (
𝜎𝑦
2 𝚺𝑦2 𝚺𝑦3
𝚺2𝑦 𝚺22 𝚺23
𝚺3𝑦 𝚺32 𝚺33
),                                                       (3.3) 
Let 𝚯 = (𝚺, 𝛃1, 𝛽0, 𝐀2, 𝐛2, 𝐀3, 𝐛3) contain all the unknown parameters for the model in 
(III.1). We can write down the negative log-likelihood function (NLLF), i.e.,  
𝑙(𝚯) = 𝑛 𝑙𝑜𝑔|𝚺| + ∑ ∑ (𝑦𝑖
(1) − 𝐱𝑖
(1𝑙)𝛃1 − 𝛽0 , 𝐱𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2 − 𝐛2, 𝐱𝑖
(3𝑙) −
𝑛𝑙
𝑖=1
4
𝑙=1
𝐱𝑖
(1𝑙)𝐀3 − 𝐛3)𝚺
−1(𝑦𝑖
(1) − 𝐱𝑖
(1𝑙)𝛃1 − 𝛽0 , 𝐱𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2 − 𝐛2, 𝐱𝑖
(3𝑙) − 𝐱𝑖
(1𝑙)𝐀3 − 𝐛3)
𝑇
.     
(3.4)           
Since 𝑙(𝚯) includes missing features from modalities 2 and 3, we cannot directly optimize 
𝑙(𝚯)  to estimate the parameters, but resort to the Expectation-Maximization (EM) 
algorithm. The general EM framework includes an E-step and an M-step. The E-step is to 
find the expectation of NLLF with respect to the missing data given the observed data and 
the current parameter estimates. The M-step is to update the parameter estimates by 
minimizing the expectation in the E-step. The two steps are iterated until convergence. The 
challenges in using the general EM framework in a specific model estimation are to derive 
the expectation specific to that model formulation in the E-step and to solve the specific 
optimization problem in the M-step. In what follows, we will develop the details for the E-
step and M-step for our specific model.  
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When the likelihood function is based on a distribution in the exponential family, Little 
and Rubin (2002) showed that the E-step becomes finding expectations of sufficient 
statistics. Our likelihood function is based on a multivariate normal distribution in (3.1). 
Therefore, the goal of the E-step is to find the sufficient statistics associate with (3.1) and 
derive their expectations. Let 𝑆 be a collection of the sufficient statistics. It can be shown 
that 
𝑆 =
{
 
 
 
 
𝐱𝑖
(21), 𝐱𝑖
(31) , 𝐱𝑖
(32), 𝐱𝑖
(24), (
(𝐱𝑖
(21))𝑇𝐱𝑖
(21) (𝐱𝑖
(31))
𝑇
𝐱𝑖
(21)
(𝐱𝑖
(21))𝑇  𝐱𝑖
(31) (𝐱𝑖
(31))
𝑇
 𝐱𝑖
(31)
) ,
 (𝐱𝑖
(32))𝑇𝐱𝑖
(32), (𝐱𝑖
(24)
)𝑇𝐱𝑖
(24)
}
 
 
 
 
. 
In the E-step at the (𝑡 + 1)-th iteration, we need to drive the expectation of 𝑆 given the 
previous estimate for 𝚯, 𝚯(𝑡), and observed data, 𝐱𝑖
𝑜𝑏𝑠 and 𝑦𝑖
𝑜𝑏𝑠, i.e.,    
𝐸(𝑆|𝐱𝑖
𝑜𝑏𝑠 , 𝑦𝑖
𝑜𝑏𝑠 , 𝚯(𝑡)).                                                                   (3.5) 
In (III.6)-(III.8) below, we first derive the expectations of the 1st -order elements in 𝑆. The 
detailed derivation process is skipped due to space limit. 
(?̃?𝑖
(21), ?̃?𝑖
(31)) = 𝐸 [(𝐱𝑖
(21), 𝐱𝑖
(31))|𝐱𝑖
(11) , 𝑦𝑖
(1), 𝚯(𝑡)] 
                        = (𝐱𝑖
(11)𝐀2
(𝑡) + 𝐛2
(𝑡), 𝐱𝑖
(11)𝐀3
(𝑡) + 𝐛3
(𝑡)) + (𝚺2𝑦
(𝑡), 𝚺3𝑦
(𝑡))(𝜎𝑦
(𝑡)2)
−1
(𝑦𝑖
(1) −
𝐱𝑖
(11)𝛃1
(𝑡) − 𝛽0
(𝑡)), (3.6)                                  
?̃?𝑖
(32) = 𝐸[𝐱𝑖
(32)|𝐱𝑖
(12) , 𝐱𝑖
(22) , 𝑦𝑖
(2),𝚯(𝑡)] 
          = 𝐱𝑖
(12)𝛃1
(𝑡) + 𝛽0
(𝑡) + (𝚺3𝑦
(𝑡), 𝚺32
(𝑡))(
𝜎𝑦
(𝑡)2 𝚺𝑦2
(𝑡)
𝚺2𝑦
(𝑡) 𝚺22
(𝑡)
)
−1
(
𝑦𝑖
(2)
−𝐱𝑖
(12)
𝛽1
(𝑡)
−𝛽0
(𝑡)
𝐱𝑖
(22)
−𝐱𝑖
(12)
𝐀2
(𝑡)
−𝐛2
(𝑡))             (3.7)                                      
?̃?𝑖
(24) = 𝐸[𝐱𝑖
(24)|𝐱𝑖
(14) , 𝐱𝑖
(34) , 𝑦𝑖
(4),𝚯(𝑡)] 
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       = 𝐱𝑖
(14)𝛃1
(𝑡) + 𝛽0
(𝑡) + (𝚺2𝑦
(𝑡), 𝚺23
(𝑡)) (
𝜎𝑦
(𝑡)2 𝚺𝑦3
(𝑡)
𝚺3𝑦
(𝑡) 𝚺33
(𝑡)
)
−1
(
𝑦𝑖
(4)
−𝐱𝑖
(14)
𝛃1
(𝑡)
−𝛽0
(𝑡)
𝐱𝑖
(34)
−𝐱𝑖
(14)
𝐀3
(𝑡)
−𝐛3
(𝑡))                        (3.8)                              
Using (3.6) -(3.8), we can further derive the expectations of the 2nd-order elements in 𝑆 as: 
𝐸
(
 (
(𝐱𝑖
(21))𝑇𝐱𝑖
(21) (𝐱𝑖
(31))
𝑇
𝐱𝑖
(21)
(𝐱𝑖
(21))𝑇𝐱𝑖
(31) (𝐱𝑖
(31))
𝑇
𝐱𝑖
(31)
) | 𝐱𝑖
(11), 𝑦𝑖
(1), 𝚯(𝑡)
)
 =
(
(?̃?𝑖
(21)
)𝑇?̃?𝑖
(21)
(?̃?𝑖
(31)
)𝑇?̃?𝑖
(21)
(?̃?𝑖
(21)
)𝑇?̃?𝑖
(31)
(?̃?𝑖
(31)
)𝑇?̃?𝑖
(31)
) + (
𝚺22|𝑦
(𝑡)
𝚺23|𝑦
(𝑡)
𝚺32|𝑦
(𝑡)
𝚺33|𝑦
(𝑡)
),   
(3.9) 
𝐸 [(𝐱𝑖
(24))
𝑇
𝐱𝑖
(24)|𝐱𝑖
(14) , 𝐱𝑖
(34) , 𝑦𝑖
(4),  𝚯(𝑡)] = (?̃?𝑖
(24)
)𝑇?̃?𝑖
(24)
+ 𝚺22|3y
(𝑡)
,                           (3.10) 
𝐸 [ (𝐱𝑖
(32))
𝑇
𝐱𝑖
(32)|𝐱𝑖
(12) , 𝐱𝑖
(22) , 𝑦𝑖
(2), 𝚯(𝑡)] = (?̃?𝑖
(32)
)𝑇?̃?𝑖
(32)
+ 𝚺33|2y
(𝑡)
                                     (3.11) 
where  
(
𝚺22|𝑦
(𝑡)
𝚺23|𝑦
(𝑡)
𝚺32|𝑦
(𝑡)
𝚺33|𝑦
(𝑡)
) = (
𝚺22
(𝑡)
𝚺23
(𝑡)
𝚺32
(𝑡)
𝚺33
(𝑡)
) − (
𝚺2𝑦
(𝑡)
𝚺3𝑦
(𝑡)) (𝜎𝑦
(𝑡)2)
−1
(𝚺𝑦2
(𝑡) 𝚺𝑦3
(𝑡)
), 
𝚺22|3y
(𝑡)
= 𝚺22
(𝑡)
− (𝚺2y
(𝑡), 𝚺23
(𝑡))(
𝜎𝑦
(𝑡)2 𝚺𝑦3
(𝑡)
𝚺3𝑦
(𝑡) 𝚺33
(𝑡)
)
−1
(
𝚺𝑦2
(𝑡)
𝚺32
(𝑡)), 
𝚺33|2y
(𝑡)
= 𝚺33
(𝑡)
− (𝚺3y
(𝑡), 𝚺32
(𝑡))(
𝜎𝑦
(𝑡)2 𝚺𝑦2
(𝑡)
𝚺2𝑦
(𝑡) 𝚺22
(𝑡)
)
−1
(
𝚺𝑦3
(𝑡)
𝚺23
(𝑡)). 
In the M-step, we find the new estimate for 𝚯, 𝚯(𝑡+1),  as the solution to the following 
equation: 
𝐸(𝑆|𝐱𝑖
𝑜𝑏𝑠 , y𝑖
𝑜𝑏𝑠 , 𝚯(𝑡)) = 𝐸(𝑆| 𝚯(𝑡)).                                       (3.12) 
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Equation (3.12) includes a set of simultaneous equations corresponding to the elements in 
𝑆. Directly solving (3.12) is not trivial. By using a notational trick, we convert the solving 
of (3.12) into obtaining least square estimators for regression coefficients. Specifically, 
denote 𝐱𝑖
(𝑘𝑙)
 by ?̃?𝑖
(𝑘𝑙)
 if 𝐱𝑖
(𝑘𝑙)
 does not contain missing features. Then, 
(𝛃1, 𝛽0, 𝐀2, 𝐛2, 𝐀3, 𝐛3) are coefficients of the following regressions:  
{
𝑦𝑖
(𝑙)
~ 𝐱𝑖
(1𝑙)𝛃1 + 𝛽0
?̃?𝑖
(2𝑙)~𝐱𝑖
(1𝑙)𝐀2 + 𝐛2
 ?̃?𝑖
(3𝑙)~𝐱𝑖
(1𝑙)𝐀3 + 𝐛3
, 
for which the coefficients can be obtained by least square estimation, i.e.,  
{
 
 
 
 
 
 (
𝛽0
(𝑡+1)
𝛃1
(𝑡+1)
) = (∑ ∑ (1, 𝐱𝑖
(1𝑙))
𝑇
(1, 𝐱𝑖
(1𝑙))
𝑛𝑙
𝑖=1
4
𝑙=1 )
−1
∑ ∑ (1,𝐱𝑖
(1𝑙))
𝑇
𝑦𝑖
(𝑙)𝑛𝑙
𝑖=1
4
𝑙=1
(
𝐛2
(𝑡+1)
𝐀2
(𝑡+1)
) = (∑ ∑ (1, 𝐱𝑖
(1𝑙))
𝑇
(1, 𝐱𝑖
(1𝑙))
𝑛𝑙
𝑖=1
4
𝑙=1 )
−1
∑ ∑ (1,𝐱𝑖
(1𝑙))
𝑇
?̃?𝑖
(2𝑙)𝑛𝑙
𝑖=1
4
𝑙=1
(
𝐛3
(𝑡+1)
𝐀3
(𝑡+1)
) = (∑ ∑ (1, 𝐱𝑖
(1𝑙))
𝑇
(1, 𝐱𝑖
(1𝑙))
𝑛𝑙
𝑖=1
4
𝑙=1 )
−1
∑ ∑ (1,𝐱𝑖
(1𝑙))
𝑇
?̃?𝑖
(3𝑙)𝑛𝑙
𝑖=1
4
𝑙=1
.                
(3.13) 
Let 𝐳𝑖
(𝑙)
= (𝑦𝑖
(1) − 𝐱𝑖
(1𝑙)𝛃1
(𝑡+1) − 𝛽0
(𝑡+1) , ?̃?𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2
(𝑡+1) − 𝐛2
(𝑡+1), ?̃?𝑖
(3𝑙) −
𝐱𝑖
(1𝑙)𝐀3
(𝑡+1) − 𝐛3
(𝑡+1)).  
Using (3.13), we can further estimate 𝚺 as follows:  
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𝚺(𝑡+1) =
1
𝑛
{∑ ∑ (𝐳𝑖
(𝑙)
)
𝑇
𝐳𝑖
(𝑙)𝑛𝑙
𝑖=1
4
𝑙=1 + 𝑛4 (
0 𝟎 𝟎
𝟎 𝚺22|3y
(𝑡)
𝟎
𝟎 𝟎 𝟎
) + 𝑛2 (
0 𝟎 𝟎
𝟎 𝟎 𝟎
𝟎 𝟎 𝚺33|2y
(𝑡)
) +
                   𝑛1(
0 𝟎 𝟎
𝟎 𝚺22|𝑦
(𝑡)
𝚺23|𝑦
(𝑡)
𝟎 𝚺32|𝑦
(𝑡)
𝚺33|𝑦
(𝑡)
)}.                                                                                      
(3.14)                                                                                       
2) Prediction 
At the convergence of the above EM iterations, we can obtain the estimated 
parameters ?̂? = (?̂?, ?̂?1, ?̂?0, ?̂?2, ?̂?2, ?̂?3, ?̂?3). Then, these parameters can be used to predict 
on new samples. Consider a new sample 𝑖∗ . Depending on what available 
modality/modalities this sample has, we can use the following model to predict the 
response variable of the sample:  
?̂?𝑖∗ = 𝐱𝑖∗
(11)
?̂?1 + ?̂?0,                                                                       if 𝑖
∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡 1; 
?̂?𝑖∗ = 𝐱𝑖
(12)(?̂?1 − ?̂?2?̂?22
−1?̂?2𝑦) + 𝐱𝑖
(22)?̂?22
−1?̂?2𝑦 + (?̂?0 − ?̂?2?̂?22
−1?̂?2𝑦),       
if 𝑖∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡 2;                               
?̂?𝑖∗ = 𝐱𝑖∗
(13) (?̂?1 − (?̂?2, ?̂?3) (
?̂?22 ?̂?23
?̂?32 ?̂?33
)
−1
(
?̂?2𝑦
?̂?3𝑦
))
+ (𝐱𝑖∗
(23) , 𝐱𝑖∗
(33)) (
?̂?22 ?̂?23
?̂?32 ?̂?33
)
−1
(
?̂?2𝑦
?̂?3𝑦
) + 
      (?̂?0 − (?̂?2, ?̂?3) (
?̂?22 ?̂?23
?̂?32 ?̂?33
)
−1
(
?̂?2𝑦
?̂?3𝑦
)),                                  if 𝑖∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡 3; 
?̂?𝑖∗ = 𝐱𝑖∗
(14)(?̂?1 − ?̂?3?̂?33
−1?̂?3𝑦) + 𝐱𝑖∗
(34)?̂?33
−1?̂?3𝑦 + (?̂?0 − ?̂?3?̂?33
−1?̂?3𝑦),    
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if 𝑖∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡 4.                      
3.3.2. IMTL classification model 
1) Formulation and estimation 
In a classification model, 𝑦𝑖
(𝑙)
 can take the values of 0 or 1 that represent two classes. 
Within each class, consider the joint distribution  𝐱𝑖
(2𝑙)
 and  𝐱𝑖
(3𝑙)
 given 𝐱𝑖
(1𝑙)
 to be 
multivariate normal, i.e.,  
(𝐱𝑖
(2𝑙) , 𝐱𝑖
(3𝑙))|𝐱𝑖
(1𝑙) , 𝑦𝑖
(𝑙) = 1 ∼ 𝑀𝑉𝑁(𝛍1(𝐱𝑖
(1𝑙)), 𝚺),                                       (3.15) 
(𝐱𝑖
(2𝑙) , 𝐱𝑖
(3𝑙))|𝐱𝑖
(1𝑙) , 𝑦𝑖
(𝑙) = 0 ∼ 𝑀𝑉𝑁(𝛍0(𝐱𝑖
(1𝑙)), 𝚺),                                      (3.16) 
We focus on linear functions of 𝛍1(∙) and 𝛍0(∙) in this paper: 
𝛍1(𝐱𝑖
(1𝑙)) = (𝐱𝑖
(1𝑙)𝐀2 + 𝐛21, 𝐱𝑖
(1𝑙)𝐀3 + 𝐛31), 
𝛍0(𝐱𝑖
(1𝑙)) = (𝐱𝑖
(1𝑙)𝐀2 + 𝐛20, 𝐱𝑖
(1𝑙)𝐀3 + 𝐛30). 
Also, we can write 𝚺 in a more explicit form to facilitate subsequent discussion, i.e., 
𝚺 = (
𝚺22 𝚺23
𝚺32 𝚺33
). 
Furthermore, we consider the distribution of 𝑦𝑖
(𝑙)
 given 𝐱𝑖
(1𝑙)
 to be Bernoulli, i.e.,   
𝑦𝑖
(𝑙) = 1|𝐱𝑖
(1𝑙)~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖 (
1
1+ exp {−𝐱𝑖
(1𝑙)
𝛃1−𝛽0}
).                                     (3.17) 
Let ?̃? = (𝚺̃, 𝛃1, 𝛽0, 𝐀2, 𝐛2, 𝐀3, 𝐛3) be the unknown parameters for the model in (3.15)-
(3.17). The NLLF is:  
𝑙(?̃?) = 𝑛 log |𝚺| + ∑ ∑ (𝑦𝑖
(𝑙)(𝐱𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2 − 𝐛21, 𝐱𝑖
(3𝑙) −  𝐱𝑖
(1𝑙)𝐀3 −
𝑙
𝑖=1
4
𝑙=1
𝐛31)𝚺
−1(𝐱𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2 − 𝐛21, 𝐱𝑖
(3𝑙) − 𝐱𝑖
(1𝑙)𝐀3 − 𝐛31)
𝑇
 + (1 − 𝑦𝑖
(𝑙)
)(𝐱𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2 −
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𝐛20, 𝐱𝑖
(3𝑙) − 𝐱𝑖
(1𝑙)𝐀3 − 𝐛30)𝚺
−1(𝐱𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2 − 𝐛20, 𝐱𝑖
(3𝑙) − 𝐱𝑖
(1𝑙)𝐀3 − 𝐛30)
𝑇
) +
𝑦𝑖
(𝑙)(𝐱𝑖
(1𝑙)𝛃1 + 𝛽0) − log (1 + exp(𝐱𝑖
(1𝑙)𝛃1 + 𝛽0)).                                                                                              
(3.18)                                                                                                                          
Equation (3.18) can be decomposed into a logistic regression and a conditional multivariate 
normal distribution. As a result, we can estimate (𝛃1, 𝛽0) and the remaining parameters in 
?̃? separately. Specifically, (𝛃1, 𝛽0) are coefficients of the logistic regression model: 
𝑙𝑜𝑔𝑖𝑡 (𝑃(𝑦𝑖
(𝑙) = 1)) = 𝐱𝑖
(1𝑙)𝛃1 + 𝛽0. 
This model does not involve missing data, which means that (𝛃1, 𝛽0) can be estimated by 
iteratively reweighted least squares (IRLS) estimation.  
Furthermore, let 𝚯 be the parameters in ?̃? excluding (𝛃1, 𝛽0). 𝚯 can be estimated by a 
similar EM algorithm to the predictive model in Section III.3.1. Here, we skip the details 
and present the result of derivations in the E-step and M-step. Specifically, the E-step 
derives the following expectations: 
(?̃?𝑖
(21), ?̃?𝑖
(31)) = 𝐸 [(𝐱𝑖
(21), 𝐱𝑖
(31))|𝐱𝑖
(11) , 𝑦𝑖
(1), 𝚯(𝑡)]       
                       = 𝑦𝑖
(1)(𝐱𝑖
(11)𝐀2
(𝑡) + 𝐛21
(𝑡), 𝐱𝑖
(11)𝐀3
(𝑡) + 𝐛31
(𝑡)) + (1 − 𝑦𝑖
(1))(𝐱𝑖
(11)𝐀2
(𝑡) +
𝐛20
(𝑡), 𝐱𝑖
(11)𝐀3
(𝑡) + 𝐛30
(𝑡)), 
?̃?𝑖
(32) = 𝐸[𝐱𝑖
(32)|𝐱𝑖
(12) , 𝐱𝑖
(22) , 𝑦𝑖
(2),𝚯(𝑡)] 
     = 𝑦𝑖
(2)(𝐱𝑖
(12)𝐀3
(𝑡) + 𝐛31
(𝑡)) + (1 − 𝑦𝑖
(2))(𝐱𝑖
(12)𝐀3
(𝑡) + 𝐛30
(𝑡)) + 𝚺32
(𝑡)(𝚺22
(𝑡))
−1
(𝐱𝑖
(22)
−
𝑦𝑖
(2)(𝐱𝑖
(12)𝐀2
(𝑡) + 𝐛21
(𝑡)) − (1 −  𝑦𝑖
(2))(𝐱𝑖
(12)𝐀2
(𝑡) + 𝐛20
(𝑡))), 
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?̃?𝑖
(24) = 𝐸[𝐱𝑖
(24)|𝐱𝑖
(14) , 𝐱𝑖
(34) , 𝑦𝑖
(4),𝚯(𝑡)] 
     = 𝑦𝑖
(4)(𝐱𝑖
(14)𝐀2
(𝑡) + 𝐛21
(𝑡)) + (1 − 𝑦𝑖
(4))(𝐱𝑖
(14)𝐀2
(𝑡) + 𝐛20
(𝑡)) +  𝚺23
(𝑡)(𝚺33
(𝑡))
−1
(𝐱𝑖
(34)
−
𝑦𝑖
(4)(𝐱𝑖
(14)𝐀3
(𝑡) + 𝐛31
(𝑡)) − (1 − 𝑦𝑖
(4))(𝐱𝑖
(14)𝐀3
(𝑡) + 𝐛30
(𝑡))). 
In the M-step, the parameters in 𝚯 can be updated as  
𝐀2
(𝑡+1)
= (∑ ∑ (𝐱𝑖
(1𝑙))
𝑇
𝐱𝑖
(1𝑙)𝑛𝑙
𝑖=1
4
𝑙=1 )
−1
∑ ∑ (𝐱𝑖
(1𝑙))
𝑇
?̃?𝑖
(2𝑙)𝑛𝑙
𝑖=1
4
𝑙=1 , 
𝐛21
(𝑡+1)
=
∑ ∑ 𝑦𝑖
(𝑙)
(?̃?𝑖
(2𝑙)
−𝐱𝑖
(1𝑙)
𝐀2
(𝑡+1)
)
𝑛𝑙
𝑖=1
4
𝑙=1
∑ ∑ (𝑦𝑖
(𝑙)
)
𝑛𝑙
𝑖=1
4
𝑙=1
, 
𝐛20
(𝑡+1)
=
∑ ∑ (1−𝑦𝑖
(𝑙)
)(?̃?𝑖
(2𝑙)
−𝐱𝑖
(1𝑙)
𝐀2
(𝑡+1)
)
𝑛𝑙
𝑖=1
4
𝑙=1
∑ ∑ (1−𝑦𝑖
(𝑙)
)
𝑛𝑙
𝑖=1
4
𝑙=1
, 
𝐀3
(𝑡+1)
= (∑ ∑ (𝐱𝑖
(1𝑙))
𝑇
𝐱𝑖
(1𝑙)𝑛𝑙
𝑖=1
4
𝑙=1 )
−1
∑ ∑ (𝐱𝑖
(1𝑙))
𝑇
?̃?𝑖
(3𝑙)𝑛𝑙
𝑖=1
4
𝑙=1 , 
𝐛31
(𝑡+1)
=
∑ ∑ 𝑦𝑖
(𝑙)
(?̃?𝑖
(3𝑙)
−𝐱𝑖
(1𝑙)
𝐀3
(𝑡+1)
)
𝑛𝑙
𝑖=1
4
𝑙=1
∑ ∑ (𝑦𝑖
(𝑙)
)
𝑛𝑙
𝑖=1
4
𝑙=1
, 
𝐛30
(𝑡+1)
=
∑ ∑ (1−𝑦𝑖
(𝑙)
)(?̃?𝑖
(3𝑙)
−𝐱𝑖
(1𝑙)
𝐀3
(𝑡+1)
)
𝑛𝑙
𝑖=1
4
𝑙=1
∑ ∑ (1−𝑦𝑖
(𝑙)
)
𝑛𝑙
𝑖=1
4
𝑙=1
, 
𝚺(𝑡+1) =
1
𝑛
{∑ ∑ (𝑦𝑖
(𝑙)
(?̃?𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2
(𝑡+1)
− 𝐛21
(𝑡+1)
, ?̃?𝑖
(3𝑙) − 𝐱𝑖
(1𝑙)𝐀3
(𝑡+1)
−
𝑛𝑙
𝑖=1
4
𝑙=1
𝐛31
(𝑡+1)
)
𝑇
(?̃?𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2
(𝑡+1) −  𝐛21
(𝑡+1), ?̃?𝑖
(3𝑙) − 𝐱𝑖
(1𝑙)𝐀3
(𝑡+1)
− 𝐛31
(𝑡+1)
) + (1 −
𝑦𝑖
(𝑙))(?̃?𝑖
(2𝑙) −  𝐱𝑖
(1𝑙)𝐀2
(𝑡+1)
− 𝐛20
(𝑡+1)
, ?̃?𝑖
(3𝑙) − 𝐱𝑖
(1𝑙)𝐀3
(𝑡+1)
−   𝐛30
(𝑡+1)
)
𝑇
(?̃?𝑖
(2𝑙) − 𝐱𝑖
(1𝑙)𝐀2
(𝑡+1)
−
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𝐛20
(𝑡+1)
, ?̃?𝑖
(3𝑙) −   𝐱𝑖
(1𝑙)𝐀3
(𝑡+1)
− 𝐛30
(𝑡+1)
)) +   𝑛4 (
𝚺22
(𝑡)
− 𝚺23
(𝑡)(𝚺33
(𝑡))
−1
𝚺32
(𝑡)
𝟎
𝟎 𝟎
) +
𝑛2 (
𝟎 𝟎
𝟎 𝚺33
(𝑡)
− 𝚺32
(𝑡)(𝚺22
(𝑡))
−1
𝚺23
(𝑡)) + 𝑛1𝚺
(𝑡)}. 
2) Prediction 
At the convergence of the above EM iterations, we can obtain the estimated 
parameters  ?̂? = (?̂?, ?̂?1, ?̂?0, ?̂?2, ?̂?2, ?̂?3, ?̂?3) . These parameters can be used in a logistic 
regression model to predict on new samples. Consider a new sample 𝑖∗. Depending on what 
available modality/modalities this sample has, i.e., which sub-cohort the sample belongs 
to, we can use the following model to predict the response variable of the sample:  
𝑃(𝑦𝑖∗
(1) = 1|𝐱𝑖∗
(11)
) = 𝑓(𝐱𝑖∗
(11)?̂?1 + ?̂?0),                                     if 𝑖
∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡1; 
𝑃(𝑦𝑖∗
(2) = 1|𝐱𝑖∗
(12) , 𝐱𝑖∗
(22)) = 𝑓 (𝐱𝑖∗
(12) (?̂?1 − ?̂?2?̂?22
−1(?̂?21 − ?̂?20)) + 𝐱𝑖∗
(22)?̂?22
−1(?̂?21 −
?̂?20) + ?̂?0 − 
1
2
?̂?21
𝑇 ?̂?22
−1?̂?21 +
1
2
?̂?20
𝑇 ?̂?22
−1?̂?20),                               if 𝑖
∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡2;    
𝑃(𝑦𝑖
(3) = 1|𝐱𝑖∗
(13) , 𝐱𝑖∗
(23) , 𝐱𝑖∗
(33)) = 𝑓 (𝐱𝑖∗
(13) (?̂?1 − (?̂?2, ?̂?3)?̂?
−1  (
?̂?21−?̂?20
?̂?31−?̂?30
)) +
(𝐱𝑖∗
(23), 𝐱𝑖∗
(33))?̂?−1  (
?̂?21−?̂?20
?̂?31−?̂?30
) + ?̂?0 − 
1
2
(?̂?21, ?̂?31)?̂?
−1 (
?̂?21
?̂?31
) +
1
2
(?̂?20, ?̂?30)?̂?
−1 (
?̂?20
?̂?30
)),                              
                                                                                                    if 𝑖∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡3; 
𝑃(𝑦𝑖
(4) = 1|𝐱𝑖∗
(14) , 𝐱𝑖∗
(34)) = 𝑓 (𝐱𝑖∗
(14) (?̂?1 − ?̂?3?̂?33
−1(?̂?31 − ?̂?30)) + 𝐱𝑖∗
(34)?̂?33
−1(?̂?31 −
?̂?30) + ?̂?0 − 
1
2
?̂?31
𝑇 ?̂?33
−1?̂?31 +
1
2
?̂?30
𝑇 ?̂?33
−1?̂?30),                                    if 𝑖
∗ ∈ 𝑠𝑢𝑏 − 𝑐𝑜ℎ𝑜𝑟𝑡4. 
𝑓(⋅) is the sigmoid function. 
3.3.3. Collaborative model estimation without data pooling 
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As mentioned previously, one reason leading to generation of IMD data in health care 
applications is that each sub-cohort corresponds to a different institution. The availability 
of modalities varies across the different institutions due to accessibility and cost. In the 
IMTL models proposed in Section 3.3.1-3.2, model estimation is assumed to happen at a 
centralized place into which the training data from different institutions (i.e., sub-cohorts) 
have been deposited. This requires a multi-institutional data sharing agreement that has 
been previously established – a process known to be time- and effort-intensive. A more 
commonly encountered scenario is that the different institutions would like to collaborate 
on model estimation without having to share their respective patients’ data. In this section, 
we address the latter scenario by proposing a modification on the EM algorithms in Section 
3.3.1-3.3.2. Figure 3.2 shows the computational architecture to support between-institution 
 
 
Figure 3.2.  Computational architecture for between-institutional/sub-cohort collaborative 
model estimation of IMTL without the need for data pooling from different sub-cohorts. 
M-step is performed by a global learner; E-step is performed locally at each sub-cohort. 
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collaborative model estimation for IMTL without the need for data pooling. The key to this 
architecture is to consider the M- and E-steps as a global and a local learner, respectively. 
The global learner resides in a centralized place while the local learners reside in each sub-
cohort. A local learner can only “see” and perform computation on the data in its respective 
sub-cohort. Results from local computation, not the data, are sent to the global learner for 
integration. Iterative communication between the global and local learners complete the 
model estimation. Specifically, the estimated parameters at the 𝑡-th iteration of the M-step, 
𝚯(𝑡), is sent to each sub-cohort/institution. Although 𝚯(𝑡) is estimated using data from all 
the sub-cohorts, the data are no longer identifiable after 𝚯(𝑡) is obtained. After receiving 
the 𝚯(𝑡), each sub-cohort performs its own E-step locally using 𝚯(𝑡) and the data specific 
to the sub-cohort. No communication is needed between the sub-cohort-wise E steps. Once 
the E-steps computations are completed, the results are sent back to M-step to compute an 
updated 𝚯(𝑡+1) . The E- and M-steps iterate until convergence. Note that the proposed 
computational architecture not only enables privacy preservation but also speeds up the 
EM iterations because sub-cohort-wise E-steps can be performed on parallel computing 
resources.  
3.4 Properties of IMTL 
In this section, we discuss two unique properties of IMTL: 1) the ability for out-of-sample 
prediction; 2) a theoretical guarantee for a larger Fisher information compared with models 
without transfer learning, which explains the outperformance of IMTL from a theoretical 
point of view.  
3.4.1. Ability for out-of-sample prediction 
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Definition: Consider a training set that includes 𝐿  sub-cohorts,  𝐷𝑡𝑟 = {𝐷𝑡𝑟,1, … ,𝐷𝑡𝑟,𝐿}. 
Each sub-cohort corresponds to a specific missing modality pattern. Further consider a test 
set 𝐷𝑡𝑒  that includes a sub-cohort whose missing modality pattern is different from all the 
sub-cohorts in 𝐷𝑡𝑟. If a model trained on 𝐷𝑡𝑟 can be used predict 𝐷𝑡𝑒 , the model is called 
capable of out-of-sample prediction.  
For example, a training set can include only sub-cohorts 1, 2, and 4 in Fig. 1 while the test 
set includes sub-cohort 3. It is obvious that the two competing methods to IMTL, i.e., SM 
and AADM, cannot do out-of-sample prediction, because they need inclusion of some data 
from sub-cohort 3 in the model training. In contrast, IMTL is capable of out-of-sample 
prediction. Next, we provide an illustrative proof for this capability of IMTL. We focus on 
the predictive model in Section III.3.1. Also, for notation simplicity, each modality is 
assumed to contain one feature. The case of multivariate features is a straightforward 
extension.  
Consider a sample 𝑖∗ in the test set who belongs to sub-cohort 3. To predict the response 
variable of this sample, (III.19) will be used, i.e.,   
?̂?𝑖∗
(3)
= 𝑥𝑖∗
(13) (?̂?1 − (?̂?2, ?̂?3) (
Σ̂22 Σ̂23
Σ̂32 Σ̂33
)
−1
(
Σ̂2y
Σ̂3y
)) +
(𝑥𝑖∗
(23), 𝑥𝑖∗
(33)) (
Σ̂22 Σ̂23
Σ̂32 Σ̂33
)
−1
(
Σ̂2y
Σ̂3y
) + (?̂?0 − (?̂?2, ?̂?3) (
Σ̂22 Σ̂23
Σ̂32 Σ̂33
)
−1
(
Σ̂2y
Σ̂3y
)).                                                                                
(3.19)                                                  
The parameters of the model in (3.19) are estimated from a training set that includes only 
sub-cohorts 1, 2, and 4 but not 3. It is easy to understand why estimation of other parameters 
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is possible except Σ23 . Intuitively, since Σ23  is the covariance between features in 
modalities 2 and 3, one would expect to have at least some training data from sub-cohort 
3, which have both modalities 2 and 3 available, in order to estimate Σ23. However, this is 
not our case. Therefore, the key to demonstrating that IMTL can do out-of-sample 
prediction is to demonstrate that the estimation for Σ23 is possible by IMTL even without 
any data from sub-cohort 3 in the training set. To show this, consider the estimation for 
Σ23 by the EM algorithm. At convergence, it can be derived that Σ23 can be estimated by 
(3.20). The detailed derivation is skipped due to space limit.   
Σ̂23 =   
1
𝑛−𝑛1−?̃?2−?̃?4
(?̃?1 − 𝑛1)Σ̂2𝑦(?̂?𝑦
2)
−1
Σ̂𝑦3 + 
1
𝑘2
∑ (𝑥𝑖
(22) − 𝑥𝑖
(12)?̂?2 − ?̂?2)(𝑦𝑖
(2) −
𝑛2
𝑖=1
𝑥𝑖
(12)(?̂?1 −        ?̂?2Σ̂22
−1Σ̂2𝑦) − 𝑥1
(22)Σ̂22
−1Σ̂2𝑦 − (?̂?0 − ?̂?2 Σ̂22
−1Σ̂2𝑦)) Σ̂𝑦3 +
1
𝑘3
∑ (𝑥𝑖
(34) −
𝑛4
𝑖=1
𝑥𝑖
(14)?̂?3 − ?̂?3)(𝑦𝑖
(4) − 𝑥𝑖
(14)(?̂?1 − ?̂?3Σ̂33
−1Σ̂3𝑦) − 𝑥1
(34)Σ̂33
−1Σ̂3𝑦 − (?̂?0 − ?̂?3 Σ̂33
−1Σ̂3𝑦))Σ̂𝑦2,    
(3.20)  
where  
𝑘2 = ?̂?𝑦
2 − Σ̂𝑦2Σ̂22
−1Σ̂2𝑦 , 
𝑘3 = ?̂?𝑦
2 − Σ̂𝑦3Σ̂33
−1Σ̂3𝑦 ,  
?̃?1 = ∑
(𝑦𝑖
(1)
−𝑥𝑖
(11)
?̂?1−?̂?0)
2
?̂?𝑦
2
𝑛1
𝑖=1 ,  
?̃?2 = ∑ (𝑥𝑖
(22) − 𝑥𝑖
(12)?̂?2 − ?̂?2)
2
(Σ̂22
−1 +
1
𝑘2
Σ̂22
−1Σ̂2𝑦Σ̂𝑦2Σ̂22
−1) −
1
𝑘2
∑ (𝑥𝑖
(22) −
𝑛2
𝑖=1
𝑛2
𝑖=1
𝑥𝑖
(12)?̂?2 − ?̂?2)
𝑇
(𝑦𝑖
(2) − 𝑥𝑖
(12)?̂?1 − ?̂?0)Σ̂𝑦2Σ̂22
−1 ,   
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?̃?4 = ∑ (𝑥𝑖
(34) − 𝑥𝑖
(14)?̂?3 − ?̂?3)
2
(Σ̂33
−1 +
1
𝑘3
Σ̂33
−1Σ̂3𝑦Σ̂𝑦3Σ̂33
−1)
𝑛4
𝑖=1  −
1
𝑘3
∑ Σ̂33
−1Σ̂3𝑦(𝑦𝑖
(4) −
𝑛2
𝑖=1
𝑥𝑖
(14)?̂?1 − ?̂?0)(𝑥𝑖
(34) − 𝑥𝑖
(14)?̂?3 − ?̂?3).  
Equation (3.20) indicates that although training data from sub-cohort 3 are not available, 
Σ23  can be estimated indirectly through a summation of three parts: The first part, 
(?̃?1 − 𝑛1)Σ̂2𝑦(?̂?𝑦
2)
−1
Σ̂𝑦3, contributes to estimating the covariance between modalities 2 
and 3 through exploiting their respective covariances with 𝑦. The second part leverages the 
training data in sub-cohort 2, and contributes to estimating Σ23 by exploring the covariance 
between residual modality 2 and residual modality 3. Here, residual modality 2 is modality 
2 after factoring out modality 1; residual modality 3 is the residual of the response variable 
regressing on modalities 1 and 2. Both residual modalities are computed using the training 
data in sub-cohort 2. Similarly, the third part leverages the training data in sub-cohort 4, 
and contributes to estimating Σ23 by exploring the covariance between residual modality 2 
and residual modality 3 that are computed on the training data in sub-cohort 4. 
3.4.2. Fisher information performance 
The next section shows better performance of IMTL than SM and AADM (i.e., models 
without transfer learning) on real data. In this section, we would like to explain the 
observed performance from a theoretical standpoint. Theorem 1 shows that the better 
performance of IMTL can be attributed to a larger Fisher information. Because Fisher 
information characterizes the variance of maximum likelihood estimators for the 
parameters of a model, a larger Fisher information means that the parameter estimation of 
IMTL has a smaller variance. For clarity of presentation, Theorem 1 is presented within 
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the context of a two-modality IMD structure with modality 2 having missing data. This 
reduces the IMTL model to: 
(𝑦𝑖
(𝑙), 𝐱𝑖
(2𝑙)) | 𝐱𝑖
(1𝑙) ∼ 𝑀𝑉𝑁 (𝛍(𝐱𝑖
(1𝑙)) , 𝚺), 
where 𝚺 = (
𝜎𝑦𝑦 𝜎𝑦2
𝜎2𝑦 𝜎22
) and 𝛀 ≜ 𝚺−1 = (
𝜃𝑦𝑦 𝜃𝑦2
𝜃2𝑦 𝜃22
). 
Theorem 1: Let 𝐼𝐼𝑀𝑅𝐿(𝜃𝑖𝑗) be the Fisher information for each element in 𝛀 under IMTL. 
Let 𝐼𝑆𝑀(𝜃𝑖𝑗) and 𝐼𝐴𝐴𝐷𝑀(𝜃𝑖𝑗) be the Fisher information under SM and AADM, 
respectively. Then,  
𝐼𝐼𝑀𝑅𝐿(𝜃𝑖𝑗) > 𝐼𝑆𝑀(𝜃𝑖𝑗) = 𝐼𝐴𝐴𝐷𝑀(𝜃𝑖𝑗), 
if the following condition holds:  
                
−𝑛1+2𝑝1+√(𝑛1−2𝑝1)
2+𝑛1𝑝1
4𝑝1
<
𝜎2𝑦
2
𝜎22𝜎𝑦𝑦
  ,                                                 (III.21) 
where 𝑛1 is the sample size of sub-cohort 1 (i.e., the sub-cohort with only modality 1 
available) and 𝑝1 is number of features of modality 1.  
Please see the proof in Appendix A. If considering 𝑛1 and 𝑝1 to be fixed (i.e., the left side 
of (III.21) is a constant), Theorem 1 indicates that the correlation between modality 2 and 
the response variable must be sufficiently large (i.e., larger than the constant) in order for 
IMTL to have a larger Fisher information than SM and AADM. The practical insight this 
Theorem provides is that IMTL will be most effective when the modality with missing data 
is a significant predictor for the response. If the modality contains largely noise with little 
predictive value, IMTL may not perform as well as models without transfer learning 
because it runs the risk of transferring noise and thus hurting the model performance. This 
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problem is known as “negative transfer” in the literature (Pan and Yang 2010). In essence, 
Theorem 1 identifies a condition to prevent negative transfer for IMTL.  
3.5 Application Case Study 
In this section, we apply IMTL to simulated and real-world datasets. Simulation 
experiments are presented in Section 3.5.1, with purposes of demonstrating the out-of-
sample prediction ability of IMTL, which the competing methods (i.e., SM and AADM) 
do not possess. Section 3.5.2 presents an application of AD diagnosis and prognosis of 
MCI patients using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset. Here, 
“diagnosis” means detection of the existence of AD pathology in the brain of an MCI 
patient. “Prognosis” means prediction if an MCI patient will progress to AD by a certain 
year of interest, e.g., 6 years. Both tasks are important for treatment and management of 
the patients.  
3.5.1. Simulation experiments 
1) Out-of-sample prediction by IMTL predictive model 
We conduct simulation experiments for the IMTL predictive model and 
classification model. For the predictive model, we first generate data for three modalities, 
i.e., 𝐱𝑖
(1𝑙)
, 𝐱𝑖
(2𝑙)
, 𝐱𝑖
(3𝑙)
, from a zero-mean multivariate normal distribution 𝑀𝑉𝑁(𝟎, 𝚺). The 
number of features in each modality is set to be 𝑝1 = 10, 𝑝2 = 𝑝3 = 5, which are close to 
the size of features in the real-world data presented in Sec. 5.1. All diagonal elements of 𝚺 
are set to be one. 𝚺 includes two parts: within-modality correlation and between-modality 
correlation. The former has been found to have little impact on the model performance and 
therefore is set to be 0.6. We investigate two settings for between-modality correlation: 0.6 
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and 0, which represent moderately strong correlation and no correlation. Furthermore, we 
investigate two training sample sizes: 300 and 150.  
Once the data for features are generated, we generate the response variable 𝑦(𝑙) by 
a linear model, 𝑦𝑖
(𝑙)
= 𝐱𝑖
(1𝑙)
𝛃1 + 𝐱𝑖
(2𝑙)
𝛃2 + 𝐱𝑖
(3𝑙)
𝛃3 + 𝛽0 + 𝜖. Here, 𝛽0 = 2; elements in 
𝛃1 , 𝛃2 , 𝛃3  are set to be 0.2; 𝜖~𝑁(0,1). Then, the simulated training data are equally 
separated into three sub-cohorts, 𝑙 = 1, 2, 4, corresponding to sub-cohorts 1, 2, and 4 in 
Fig. 1. To obtain the incomplete modality pattern in each sub-cohort, we remove the 
training data of modalities 2 and 3 for sub-cohort 1, remove modality 3 for sub-cohort 2, 
and remove modality 2 for sub-cohort 4. Because our intention of this experiment is to 
assess the out-of-sample prediction capability of IMTL, we generate data in a test data that 
includes only sub-cohort 3, i.e., all modalities are available. The sample size of the test set 
is 100.  
IMTL is trained on the training set that includes only data from sub-cohorts 1, 2, 
and 4. Then, the trained model is used to predict on the test set that only includes samples 
from sub-cohort 3. The predicted response variables of the test set is compared with the 
true responses to compute a prediction mean square error (PMSE) and a Pearson correlation 
(PC). We repeat the entire experiment for 100 times. Table III.1 summarizes the results. 
As expected, increasing the training sample size significantly improves PMSE and PC 
(p<0.001). The correlation between modalities also helps improves PMSE and PC 
(p<0.001). This is consistent with the theoretical discovery in Section 3.4.1, in which we 
found that the key to out-of-sample prediction was to be able to estimate Σ23 from the 
training data. From (3.20), it is known that the estimation of Σ23  is affected by the 
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correlation between modality 2 and 3. Even though the training data does not include 
samples with both modality 2 and 3 available, Σ23 can still be estimated indirectly by IMTL 
through exploiting the between-modality correlation and the relationship between 
modalities and the response variable.  
 
  
2) Out-of-sample prediction by IMTL classification model 
The data generation process of this experiment is the same as the previous section except 
that we use a logistic regression model to link the response variable with predictors/features. 
Specifically, we first simulate a linear predictor 𝑧𝑖
(𝑙)
= 𝐱𝑖
(1𝑙)
𝛃1 + 𝐱𝑖
(2𝑙)
𝛃2 + 𝐱𝑖
(3𝑙)
𝛃3 +
𝛽0 + 𝜖. Then, 𝑦𝑖
(𝑙)
 is generated from a Bernoulli distribution with success probability equal 
to 1 (1 + 𝑒−𝑧𝑖
(𝑙)
)⁄  . Test accuracy is reported as the Area Under the Curve (AUC). Table 
3.2 summarizes the results. Doubling the training sample size does not seem to dramatically 
improve the AUC although this improvement is still statistically significant (p<0.001). The 
correlation between modalities also helps improve the AUC significantly (p<0.001).  
Table 3.1A Out-of-sample prediction accuracy on the test set with different training 
sample sizes (between-modality correlation is kept as 0.6 in both settings) 
Training size PMSE: 𝑎𝑣𝑒(𝑠𝑡𝑑) PC: 𝑎𝑣𝑒(𝑠𝑡𝑑) 
300 1.174 (0.175) 0.945 (0.010) 
150 1.469 (0.289) 0.931 (0.017) 
 
Table 3.1B Out-of-sample prediction accuracy on the test set with different between-
modality correlations (training sample size is kept as 300 in both settings) 
Between-modality 
correlation 
PMSE: 𝑎𝑣𝑒(𝑠𝑡𝑑) PC: 𝑎𝑣𝑒(𝑠𝑡𝑑) 
0.6 1.174 (0.175) 0.945 (0.010) 
0 1.300 (0.187) 0.866 (0.028) 
 
 
59 
 
 
3.5.2. Early diagnosis and prognosis of AD 
1) Introduction to ADNI  
ADNI (http://adni.loni.ucla.edu) was launched in 2003 by the NIH, FDA, private 
pharmaceutical companies, and non-profit organizations, as a $60 million, 5-year public-
private partnership. The primary goal of ADNI has been to test whether MRI, PET, other 
biological markers, and clinical and neuropsychological assessment can be combined to 
measure the progression of MCI and early AD. Determination of sensitive and specific 
markers of very early AD progression is intended to aid researchers and clinicians to 
develop new treatments and monitor their effectiveness, as well as lessen the time and cost 
of clinical trials. The Principal Investigator of this initiative is Michael W.Weiner, MD, 
VA Medical Center and University of California-San Francisco. ADNI is the result of 
efforts of many co-investigators from a broad range of academic institutions and private 
corporations, and subjects have been recruited from over 50 sites across the US and Canada. 
For up-to-date information, see http://www.adni-info.org/. 
2) Patient inclusion and diagnostic/prognostic end points 
Table 3.2A Out-of-sample classification accuracy on the test set with different training 
sample sizes (between-modality correlation is kept as 0.6 in both settings) 
Training size AUC: 𝑎𝑣𝑒(𝑠𝑡𝑑) 
300 0.882 (0.037) 
150 0.832 (0.05) 
 
Table 3.2B Out-of-sample classification accuracy on the test set with different between-
modality correlations (training sample size is kept as 300 in both settings) 
Between-modality correlation AUC: 𝑎𝑣𝑒(𝑠𝑡𝑑) 
0.6 0.882 (0.037) 
0 0.781 (0.046) 
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Our study includes 214 MCI patients from ADNI through our collaborative intuition, 
Banner Alzheimer’s Institute (BAI), with which two co-authors are affiliated. BAI is a 
member of ADNI PET core (PI, William Jagust UC Berkeley). Multimodality image data 
include MRI, FDG-PET, amyloid-PET, which follow the IMD structure in Fig. 1. Each 
sub-cohort has the same sample size. For diagnosis, we use A𝛽 positivity is an indicator 
for high-risk AD. We follow the recommendation by Fleisher et al. (2011) and use a 
threshold of mean SUVR greater than or equal to 1.18 to define A𝛽 positivity. According 
to this criterion, there are 87 and 127 patients in class 1 (high-risk) and 0 (otherwise). For 
prognosis, the purpose is to predict when an MCI patient will convert to AD. We searched 
the ADNI database for the 214 patients from the time when their imaging data were 
collected up to six years’ follow up, and found that 46 converted to AD, i.e., there are 46 
and 168 converters (class 1) and non-converters (class 0).  
3) Image processing and feature computation 
For MRI images, we use the FreeSurfer (http://surfer.nmr.mgh.harvard.edu/) software to 
extract volumetric measurements for pre-defined regions of interest (ROIs). We focus on 
three ROIs including hippocampal, ventricle, and entorhinal volumes relative to 
intracranial volume. All three have been widely reported to be related to AD (Devanand et 
al. 2007; Thompson et al. 2004) . Both FDG-PET and amyloid-PET are PET images, so 
they share the same image processing step in which we use SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/) to spatially normalize each patient’s PET images into 
the common Montreal Neurological Institute (MNI) altas space. Then, we extract features 
from each type of PET image separately. From FDG-PET, the features include 
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hypometabolic convergence index (HCI) (Chen et al. 2011), statistical region of interest 
(sROI) (Chen et al. 2010), and regional precuneus metabolism and posterior cingulate 
metabolism. All these features have been previously reported to be related to AD  (Bailly 
et al. 2015; Del Sole et al. 2008). From amyloid-PET, the features include SUVRs from 
six brain regions including orbital frontal cingulate, temporal cortex, anterior cingulate, 
posterior cingulate, parietal lobe, and precuneus. These regions are known to be associated 
with amyloid depositions and AD (Fleisher et al. 2011). Because the six SUVRs are highly 
correlated, we apply principal component analysis (PCA) and include the first PC as a 
feature for amyloid-PET. 
4) Inclusion of clinical variables and feature screening 
We also include the following clinical variables which could potentially help the early 
diagnosis and prognosis of AD: age, gender, years of education, APOE e4 status, and 
cognitive test scores from several commonly used instruments such as mini-mental state 
examination (MMSE), AD assessment scale-cognitive (ADAS-Cog), clinical dementia 
rating (CDR), and auditory verbal learning test (AVLT). No patient has missing data for 
these clinical variables so they are used in the same way as MRI features in our model. 
Furthermore, we put all the features through a feature screening module using the approach 
by (Fan and Lv 2008). Note that feature screening is only applied to the training set not the 
entire dataset to avoid overfitting. 
5) Application of IMTL 
Within each sub-cohort, the samples are divided into five folds. We combine four folds 
from each sub-cohort into a training set and use the remaining data as the test set. We apply 
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IMTL to the training set and then use the trained model to predict on the test set. We 
exhaust all four-fold combinations in training, which produces a 5-fold cross validation 
procedure for evaluating the accuracy of IMTL. This process is repeated for 50 times. For 
comparison, two competing methods are applied on the same data: SA and AADM. Table 
3.3 summarizes the results. IMTL has significantly higher AUC and sensitivity than both 
competing methods in both diagnosis and prognosis. Notably, competing methods have 
low AUC and sensitivity in prognosis. This is greatly improved by IMTL. Prognosis is 
more challenging than diagnosis because the former has a heavily imbalanced dataset (46 
converters vs. 168 non-converters). Clearly, IMTL is more robust to sample imbalance. All 
models achieve similar levels of specificity. Finally, we show the contribution of each 
imaging feature to diagnosis and prognosis by plotting the percentage of times a feature is 
included in the IMTL model. The result is shown in Figure 3.3. Hippocampal volume from 
MRI and the first PC of six SUVRs from amyloid-PET are almost always included in both 
diagnostic and prognostic models. This is consistent with findings in the literatures that 
hippocampal atrophy and amyloid-PET SUVRs provide most important biomarkers for AD 
(Fleisher et al. 2011; Devanand et al. 2007). Other features that are selected for over 50% 
of the time include HCI, sROI and precuneus metabolism from FDG-PET for diagnosis; 
and ventricle volume from MRI and HCI and sROI from FDG-PET for prognosis.  
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Table 3.3 Diagnostic and prognostic performance: ave (std) and p value for hypothesis 
testing that IMTL is better than a competing method 
     DIAGNOSIS PROGNOSIS 
 IMTL SM AADM IMTL SM AADM 
AUC 0.93(0.03) 0.86(0.06) 0.90(0.04) 0.85(0.05) 0.72(0.09) 0.78(0.07) 
  p<0.001 p<0.001  p<0.001 p<0.001 
SENSITIVITY 0.91(0.06) 0.84(0.09) 0.88(0.06) 0.96(0.09) 0.58(0.18) 0.76(0.17) 
  p<0.001 p=0.03  p<0.001 p<0.001 
SPECIFICITY 0.87(0.06) 0.82(0.06) 0.86(0.05) 0.85(0.05) 0.86(0.05) 0.86(0.05) 
  p<0.001 p=0.27  p=0.78 p=0.34 
 
 
Figure 3.3.  Percentage of times imaging features are included in IMTL over 5-fold cross-
validation and 50 repeated experiments. 
3.6 Conclusion 
In this paper, we proposed IMTL to build predictive and classification models for IMD 
data. We developed an EM algorithm for parameter estimation of IMTL and further 
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extended it to achieve between-institutional collaborative model estimation without the 
need for data pooling. We demonstrated that IMTL was capable of out-of-sample 
prediction and proved that it has a larger Fisher information than models without transfer 
learning under mild conditions. This explained the outperformance of IMTL from a 
theoretical standpoint. Simulation experiments demonstrated high accuracy in using IMTL 
for out-of-sample prediction and classification. IMTL was applied for AD early diagnosis 
and prognosis, i.e., at the MCI stage, using incomplete multimodality imaging data. 
Significantly higher AUC and sensitivity were achieved in both diagnosis and prognosis 
compared with competing methods. Image features selected to include in the models were 
widely-reported in the literature to be related to AD. Future research may include extension 
to non-linear models and categorical features as well as application of IMTL to other 
application domains. 
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CHAPTER 4 
A HOTSPOT SEARCH ALGORITHM FOR FUSION OF 3-D RADIATION DOSE 
MAP AND PATIENT CHARACTERISTICS WITH APPLICATION IN CARDIAC 
TOXICITY ASSESSMENT OF LUNG CANCER  
 
 
4.1 Introduction 
Lung cancer is a fatal disease which caused 150,000 deaths in year 2018 alone. Low 
survival rate is a main characteristic of lung cancer. In the U.S., around 15% of patients 
with lung cancer can survive for five years after the diagnosis, and this number is much 
lower in the developing world (Majumdar, 2009).  One of the most common treatment for 
lung cancer is the radiation therapy (RT). However, the side effect of the RT is that the 
radiation dose may also cause injury on normal tissues while killing cancer cells. As 
location of lungs is close to the heart, radiation damage on the heart has been known as 
“cardiac toxicity” (Belliere et al., 2013; Hardy et al., 2010; Cella et al., 2014). Cardiac 
toxicity can cause heart damage that may overrule the benefit of RT in treating the lung 
cancer, leading to shortening of the overall survival (OS). In fact, recent clinical trials on 
using radiation dose escalation protocols to treat lung cancer found unexpected results of 
decrease in OS, despite the fact that dose escalation has been found to be an effective 
approach in treating other cancers (Zelefsky et al., 2008). This suggests that lung cancer 
patients receiving dose escalation may have suffered from early onset cardiac toxicity 
because of the tumor location, which may reduce the OS (Lancellotti et al., 2013; Bradley 
et al., 2015; Chun et al., 2017).  
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There is an urgent need to understand how radiation dose on the heart affects the 
OS of lung cancer patients, which will help optimize RT treatment planning to minimize 
damage to the heart. Not much work has been done so far, because this is an emerging area 
that has just recently caught the attention of medicine. Among the few existing studies, the 
commonly adopted approach is to collapse the 3-D dose map of the heart into a 1-D dose-
volume histogram (DVH), and then build univariate or multivariate models to correlate 
features extracted from the histogram with OS. Here, a 3-D dose map contains the dose 
level (in unit of Gy) on each voxel of a 3-D image (e.g., CT or MRI) of the heart. A 1-D 
histogram is constructed by counting the frequency of voxels of the heart (y axis) that have 
a certain dose level (x axis). The conversion from a 3-D dose map to a 1-D histogram has 
an obvious limitation that spatial information of the dose distribution is lost.   
This paper has a different perspective from the existing histogram-based studies. 
We would like to avoid the conversion and the associated loss of spatial information, and 
use the 3-D dose map directly. In particular, our objective is to find if there is any sub-
region of the heart, referred to as a hot spot, which is a significant biomarker for cardiac 
toxicity.  
The contribution of this study is multifold: 
• Methodological development: We propose a novel mathematical 
formulation of the 3-D spatial hot spot search problem, by integration 
generalized linear model (GLM) and a proposed definition of the hot spot, 
which includes both a location/sub-region of the heart and a dose threshold. 
This definition facilitates inclusion of the found hot spot into the existing 
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treatment planning software to minimize cardiac toxicity. Furthermore, 
under the proposed mathematical formulation, we develop a novel search 
algorithm for the hot spot, in which search of the dose threshold is 
theoretically proven to be equivalent to the search of this threshold on the 
whole heart. Under the found optimal dose threshold, search of the hot spot 
location can be further accomplished by scanning over the units of the heart 
using a unit-wise GLM.  
• Application impacts: We apply the proposed algorithm to a dataset 
containing patients with Non-Small Cell Lung Cancer (NSCLC) who 
received Intensity Modulated Radiation Therapy (IMRT) at Mayo Clinic 
Arizona. The hot spot sub-region found by our algorithm harbors the 
sinoatrial node of the electronic conduction system of the heart. Damage of 
the sinoatrial node by radiation toxicity disrupts the crucial function of the 
heart, leading to shortening of OS. Our finding suggests that protective 
strategies may be developed to spare the susceptible hot spot, and thus 
helping RT planning achieve the optimal result in treating lung cancer 
patients.  
The remainder of this paper is structured as follows: Section 2 provides the 
literature review and points out limitations of the existing research, which motivates the 
research in this paper. Section 3 presents the mathematical formulation of the hot spot 
search problem. Section 4 presents the algorithm development for hot spot search. Section 
5 presents a case study based on real data. Section 6 is conclusion.   
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4.2 Literature Review 
 
Cardiac toxicity has been studied for lung cancer. As locations of the lungs are close 
to the heart, radiation therapy intended to treat the cancer inevitably spills radiation dose 
to the heart. Because radiation dose maps of the heart are 3-D, a challenging issue is what 
features to extract from a 3-D map to correlate with the response variable (e.g., OS, 
development of heart disease, etc). To tackle this challenge, most existing research converts 
the 3-D map into a DVH, which plots the fractional volume of the heart that receives a 
certain dose level (Fig. 4.1). Then, features are extracted from the DVH. Specifically, 
denote the DVH by 𝑓(𝑥), where 𝑥 is the dose variable ranging from 0 to the maximum 
dose, 𝑚𝑎𝑥𝑥, and 𝑓 is the fractional volume of the heart that receives dose level 𝑥. A typical 
feature extracted from 𝑓(𝑥) is the fractional volume of the heart that receives dose greater 
than a threshold 𝐷, denoted by 𝑉𝐷  (Fig. 4.1). By definition, 𝑉𝐷 = 𝑃(𝑥 > 𝐷). The rationale 
behind such a feature is that there is a tipping- point dose level 𝐷∗, which if exceeded, may 
lead to heart tissue damage that is hard to repair (Hendry, 2015). However, because 𝐷∗ is 
unknown, different values of 𝐷 may be used, resulting in a set of 𝑉𝐷’s, which are linked 
with the response variable by a statistical model. Depending on the type of the response 
variable, classification models (for categorical response), predictive models (for 
continuous response), or cox models (for censored data) may be used. Next, we provide 
more detailed review for the existing research on cardiac toxicity. Note that because the 
area of cardiac toxicity of lung cancer is fairly new, there are not many papers yet and most 
papers were published in the past two years.  
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Figure. 4.1: Example of a DVH and definition of the fractional volumetric 
variable 𝑉𝐷  
Speirs et al. (2017) investigated cardiac toxicity of 251 patients with locally 
advanced NSCLC. Fractional volumetric variables 𝑉5 to 𝑉75 by 5Gy apart were extracted 
from the DVH of the heart and then binarized using cutoffs.  Using a univariate Cox model, 
the paper found that OS would be worsened if the binarized factional volumetric variables 
from 𝑉5 to 𝑉60  were increased. Moreover, a multivariate Cox model was also fit, which 
included 𝑉50 , heart volume, mean lung dose, bilateral information, and the left lower lobe 
tumor location as predictors. 𝑉50 was found to be associated with OS. Wang et al. (2017) 
studied cardiac toxicity of 112 patients with stage III NSCLC. Symptomatic cardiac events 
and time to death or last follow-up were used as clinical endpoints. Fractional volumetric 
variables 𝑉5 ,  𝑉30 and mean dose were extracted from the DVH of the heart, all of which 
were found to be significant in univariate survival analysis. The paper concluded that 
cardiac events were associated with radiation doses to the heart. Stam et al. (2017) 
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investigated cardiac toxicity of 803 patients with stage I-II NSCLC, who were treated with 
Stereotactic Body Radiation Therapy (SBRT). A multivariate Cox model was used to 
identify doses to the heart structure that may be associated with non-cancer death. The 
paper found that maximum dose to the left atrium and the dose to 90% of the superior vena 
cava were significant associated with non-cancer death. Johnson et al. (2017) proposed a 
match-pair analysis between NSCLC IIIB patients receiving standard dose RT (43 patients) 
and those receiving high dose RT (43 patients). The paper performed univariate and 
multivariate analysis using 𝑉5 and 𝑉30  of the heart, and found that 𝑉30 was associated with 
OS.  
However, the existing studies share the same limitation that they built models using 
features extracted from DVH of the heart. As DVH collapses the 3-D dose map into a 1-D 
histogram, spatial distribution of radiation dose on the heart is lost. Because different parts 
of the heart have different functions, there is regional heterogeneity within the heart in 
terms of susceptibility to radiation damage. Therefore, a new model is needed that can 
search a sub-region of the heart – referred to as the “hot spot” in this paper – whose 
fractional volumetric variables are significant predictors to inform cardiac toxicity. This 
has not been studies in the existing literature and is the goal of this paper.  
4.3 Mathematical Formulation for the Hot Spot Search Problem 
We first propose the definition of a hot spot as follows. 
Definition 1 (hot spot): Let 𝑟  be a sub-region of the heart. Let 𝑉𝐷
(𝑟)
 be the fractional 
volumetric variable extracted from the DVH of region 𝑟. That is, 𝑉𝐷
(𝑟)
 is the fractional 
volume of region 𝑟 that receives dose greater than 𝐷. A hot spot is a minimum region 𝑟∗ 
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for which there exists a 𝐷∗ such that 𝑉𝐷∗
(𝑟∗)
 is positively associated with cardiac toxicity, i.e., 
the larger that the 𝑉𝐷∗
(𝑟∗)
, the higher the toxicity.  
According to the definition, the concept of a hot spot includes both a sub-region of 
the heart, 𝑟∗, and a dose threshold 𝐷∗. Therefore, we use to (𝑟∗, 𝐷∗) to represent a hot spot 
in this paper. Definition 1 also reveals the challenge for a hot spot search algorithm, i.e., 
the algorithm will need to search not only a sub-region 𝑟∗ of the heart but also the dose 
threshold 𝐷∗ . Furthermore, we would like to clarify a few important points regarding 
Definition 1:  
(1) A hot spot is not a sub-region receiving high radiation dose. Instead, it is a sub-
region that is sensitive to radiation dose, i.e., the larger the fractional volume of this sub-
region that receives dose greater than 𝐷∗, the more severe of the cardiac toxicity.  A sub-
region receiving high radiation dose for a particular patient may not be a hot spot if that 
sub-region is insensitive to dose, i.e., how much dose is received and how the dose is 
distributed spatially within that sub-region will have little impact on toxicity.  
(2) A hot spot is not a sub-region whose average dose is positively associated with 
cardiac toxicity. Instead, it is a sub-region whose volumetric feature 𝑉𝐷∗
(𝑟∗)
 is associated 
with cardiac toxicity. The latter is biologically justified as being the factional volume of a 
sub-region receiving radiation dose greater that a tipping point 𝐷∗ that may lead to tissue 
damage beyond repair. Also, 𝑉𝐷∗
(𝑟∗)
, once found, can be incorporated into the current 
treatment planning optimization software which uses volumetric features as a constraint 
when developing the optimal RT plan for a patient.  
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(3) A hot spot is a minimum sub-region for which the stated condition in Definition 
1 holds. It is possible for a superset sub-region of the hot spot sub-region to also satisfy the 
condition, but the superset is not the hot spot we are looking for because it includes subset 
sub-regions other than the hot spot for which the condition does not hold. Finding the 
minimum sub-region has a clear benefit for treatment planning, i.e., the smaller a sub-
region needs to be protected from radiation damage, the easier for the treatment planning 
software to accommodate this constraint without compromising dose delivery to the tumor.  
(4) In order to operationalize Definition 1 to guide the search of the hot spot, one 
will need to define the clinical endpoint the measures cardiac toxicity. There are multiple 
ways to measure cardiac toxicity. Direct measures include physiological changes of the 
heart after being exposed to radiation, such as cardiac ischemia, pleural, pericardial 
effusions, and heart failure (Beukema et al., 2015). However, unless through specially 
designed clinical trials to assess cardiac toxicity, these direct measures are not collected in 
routine clinical practice for treating cancer patients. Indirect measures are more commonly 
used, with the most common one being the OS. Most existing studies on cardiac toxicity 
as reviewed in Section 2 used OS. In this paper, our proposed method can be applied to 
any direct or indirect measure of cardiac toxicity, which is generally called the response 
variable.  
Next, we introduce the mathematical formulation for the hot spot search problem. 
Let 𝑦𝑖, 𝑀𝑖, and 𝐙𝑖 be the response variable, 3-D dose map of the heart, and covariates for 
patient 𝑖, respectively. 𝑦𝑖  can be categorical/binary (e.g., development of heart diseases, 
death by a pre-specified number of years), continuous (e.g., severity of the heart diseases), 
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or censored (e.g., OS). Given 𝑟 and 𝐷, 𝑉𝐷,𝑖
(𝑟)
 that can be computed from 𝑀𝑖.  𝐙𝑖 contains 
demographic variables and other clinical variables that may potentially impact the response 
variable beyond 𝑀𝑖, such as cancer stage, location of tumor, and concurrent therapy. We 
adopt a generalized linear model (GLM) to link 𝑦𝑖  with predictors 𝐙𝑖 and 𝑉𝐷,𝑖
(𝑟)
, in order to 
accommodate all the aforementioned types of the response variable 𝑦𝑖. In a GLM, 𝑦𝑖 has a 
distribution from exponential family that takes the following form:  
𝑓(𝑦𝑖) = exp {
𝑦𝑖𝜃𝑖−𝑏(𝜃𝑖)
𝑎(𝜙)
+ 𝑐(𝑦𝑖 , 𝜙)},                                           (4.1) 
where 𝜙  and 𝜃𝑖  are called the dispersion parameter and the canonical parameter, 
respectively; 𝑎(⋅), 𝑏(⋅) and 𝑐(⋅) are known functions.  To link 𝑦𝑖  with predictors 𝐙𝑖  and 
𝑉𝐷,𝑖
(𝑟)
, a link function 𝑔(⋅) is used, i.e.,  
𝑔(𝜇𝑖) = 𝛃
𝑇𝐙𝑖 + 𝛾𝑉𝐷,𝑖
(𝑟)
,   or equivalently 𝜇𝑖 = 𝑔
−1(𝛃𝑇𝐙𝑖 + 𝛾𝑉𝐷,𝑖
(𝑟)
),                       (4.2) 
where 𝜇𝑖 is the mean of 𝑦𝑖. It is known that 𝜃𝑖 in (4.1) can be written as a function of 𝜇𝑖, 
i.e., 𝜃𝑖 = 𝜃(𝜇𝑖). Inserting the 𝜇𝑖 in (2) into 𝜃(𝜇𝑖), we can get 
𝜃𝑖 = 𝜃(𝑔
−1(𝛃𝑇𝐙𝑖 + 𝛾𝑉𝐷,𝑖
(𝑟)
)).                                              (4.3) 
Inserting (4.3) into (4.1), we can write the log-likelihood function for the unknown 
parameters of the model as  
𝑙(𝛃, 𝛾, 𝑟, 𝐷) = ∑
𝑦𝑖𝜃(𝑔
−1(𝛃𝑇𝐙𝑖+𝛾𝑉𝐷,𝑖
(𝑟)
))−𝑏(𝜃(𝑔−1(𝛃𝑇𝐙𝑖+𝛾𝑉𝐷,𝑖
(𝑟)
)))
𝑎(𝜙)
+ 𝑐(𝑦𝑖 , 𝜙)
𝑛
𝑖=1 .                  (4.4) 
We can use maximum likelihood estimation (MLE) to estimate the unknown parameters 
in (4.4) by solving the following optimization:  
                                            (𝛃∗, 𝛾∗, 𝑟∗, 𝐷∗) = 𝑎𝑟𝑔𝑚𝑎𝑥  𝑙(𝛃, 𝛾, 𝑟, 𝐷).                           (4.5) 
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 (4.5) is not straightforward to solve because it includes two additional unknown 
parameters, 𝑟 and 𝐷, beyond the regular MLE for a GLM.  
4.4 Algorithm Development for Hot Spot Search 
4.4.1 Finding 𝐷∗ in the hot spot search 
The optimization problem in (4.5) would be easier to solve if either 𝑟∗ or 𝐷∗ were 
known ahead of time. Theorem 1 reveals a nice property of our problem formulation, which 
implies that 𝐷∗ can be found from the DVH of the whole heart. Then, the found 𝐷∗ can be 
“plugged” into (4.5) to solve for 𝛃∗, 𝛾∗ and 𝑟∗.  
Proposition 1: Let (𝑟∗, 𝐷∗)  be a hot spot. Let 𝐶𝑜𝑣 (𝑔(𝜇), 𝑉𝐷∗
(𝑟∗)
|𝐙  )  be the partial 
covariance between the linear predictor of the GLM, 𝑔(𝜇), and 𝑉𝐷∗
(𝑟∗)
, given the patient 
covariates 𝐙. 𝐶𝑜𝑣 (𝑔(𝜇), 𝑉𝐷∗
(𝑟∗)
|𝐙  ) > 0 according to Definition 1. Then, we have 
𝐶𝑜𝑣(𝑔(𝜇), 𝑉𝐷∗
(𝐻)
|𝐙  ) > 0, 
where 𝑉𝐷∗
(𝐻)
 denotes the fractional volumetric variable extracted from the DVH of the 
whole heart.  
Please see the proof of Theorem 1 in the Appendix. Driven by Theorem 1, we can 
find the optimal 𝐷∗ of the optimization problem in (4.5) by solving (4.5) on the whole heart 
(i.e., consider 𝑟 to be the whole heart), i.e., 
(𝛃(𝐻),  𝛾(𝐻), 𝐷∗) = 𝑎𝑟𝑔𝑚𝑎𝑥    𝑙(𝛃, 𝛾, 𝐷|𝑟 = 𝐻).                               (4.6) 
To solve (4.6), we can alternate between two sub-optimizations: Given 𝐷, (6) becomes the 
MLE for a regular GLM; given (𝛃, 𝛾), the optimization with respect to 𝐷 can be solved by 
a Quasi-Newton method (Byrd et al., 1995; Zhu et al., 1997). The two sub-optimizations 
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will be solved iteratively until convergence. The convergence property is guaranteed by 
Proposition 2, which shows that the likelihood function in (4.6) keeps increasing through 
the iterative steps between the two sub-optimizations. The proof of Proposition 2 is skipped. 
We summarize the steps in solving (4.6) in Algorithm 1.  
Proposition 2: Let 𝑙(𝛃𝑗 , 𝛾𝑗 , 𝐷𝑗|𝑟 = 𝐻) be the likelihood function in (6) at the 𝑗-th iteration 
of the optimization algorithm. Let 𝑙(𝛃𝑗+1, 𝛾𝑗+1, 𝐷𝑗|𝑟 = 𝐻) be the likelihood function under 
fixed 𝐷𝑗 while 𝛃𝑗+1 and 𝛾𝑗+1 are obtained by MLE. Let 𝑙(𝛃𝑗+1, 𝛾𝑗+1, 𝐷𝑗+1|𝑟 = 𝐻) be the 
likelihood function under fixed while 𝛃𝑗+1 and 𝛾𝑗+1 while 𝐷𝑗+1 is obtained by the Quasi-
Newton method.  Then we have  
𝑙(𝛃𝑗, 𝛾𝑗 , 𝐷𝑗|𝑟 = 𝐻) ≤ 𝑙(𝛃𝑗+1, 𝛾𝑗+1, 𝐷𝑗|𝑟 = 𝐻) ≤ 𝑙(𝛃𝑗+1, 𝛾𝑗+1, 𝐷𝑗+1|𝑟 = 𝐻). 
Algorithm 1 (Find 𝐷∗ in the hot spot search) 
Input: 𝑦𝑖(𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒), 𝑀𝑖(3 − 𝐷 𝑑𝑜𝑠𝑒 𝑚𝑎𝑝 𝑜𝑓 𝑡ℎ𝑒 ℎ𝑒𝑎𝑟𝑡), and 𝐙𝑖(𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠) for a 
set of patients 𝑖 = 1,… , 𝑛. 
Initialization:  (𝛃, 𝛾, 𝐷) = (𝛃0, 𝛾0, 𝐷0) 
Iterate between 1) and 2) till convergence; at the 𝑗 -th iteration, do the following: 
1) Given 𝐷 = 𝐷𝑗 , use MLE to solve the optimization in (6) and get estimation 
(𝛃𝑗+1, 𝛾𝑗+1); 
2) Given (𝛃, 𝛾) = (𝛃𝑗+1, 𝛾𝑗+1) , use the Quasi-Newton method to solve the 
optimization in (4.6) and get 𝐷𝑗+1. 
Output: 𝐷∗ at convergence (𝛃(𝐻),  𝛾(𝐻) can also be obtained but they are side products 
that will not be used in the subsequent estimation.) 
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4.4.2 Finding 𝑟∗ in the hot spot search 
Under the 𝐷∗ found by Algorithm 1, we will need to further find the hot spot sub-
region 𝑟∗ the heart. Suppose the 3-D heart 𝐻 is composed by 𝑁 indexed units, i.e., 𝐻 =
{𝑠𝑘}𝑘=1,…,𝑁. Theoretically speaking, a unit of the heart can be as small as a voxel on the 3-
D dose map. In practice, a unit should include a sufficient number of voxels to allow for 
construction of a DVH for the unit. On the other hand, a too large unit is also not 
appropriate because if the size of the hot spot is even smaller than the unit, we will not be 
able to find the shape of the hot spot to a good precision. Determining an appropriate unit 
is study-dependent.  
A hot spot 𝑟∗ is composed by a subset of units of the heart. In order to identify the 
units included in the hot spot, we can compute 𝐶𝑜𝑣(𝑔(𝜇), 𝑉𝐷∗
(𝑠𝑘)|𝐙  ) for each unit of the 
heart, 𝑘 = 1,… , 𝑁 , and identify the units with 𝐶𝑜𝑣(𝑔(𝜇), 𝑉𝐷∗
(𝑠𝑘)|𝐙  ) > 0 . Denote the 
collection of these units by Ω, i.e., Ω = {𝑠𝑘|𝐶𝑜𝑣 (𝑔(𝜇), 𝑉𝐷∗
(𝑠𝑘)|𝐙  ) > 0, 𝑘 = 1,… , 𝑁}. By 
definition, we know that Ω is the hot spot 𝑟∗.  
An empirical approach for finding units with 𝐶𝑜𝑣(𝑔(𝜇), 𝑉𝐷∗
(𝑠𝑘)|𝐙  ) > 0 is to fit a 
GLM with 𝑉𝐷∗
(𝑠𝑘) and 𝐙 as predictors. If the coefficient for 𝑉𝐷∗
(𝑠𝑘) is significantly greater than 
zero, it is evidence that 𝐶𝑜𝑣(𝑔(𝜇), 𝑉𝐷∗
(𝑠𝑘)|𝐙  ) > 0. We summarize steps in finding the hot 
spot sub-region in Algorithm 2.  
Algorithm 2 (Find 𝑟∗ in the hot spot search) 
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Input: 𝑦𝑖(𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒), 𝑀𝑖(3 − 𝐷 𝑑𝑜𝑠𝑒 𝑚𝑎𝑝 𝑜𝑓 𝑡ℎ𝑒 ℎ𝑒𝑎𝑟𝑡), and 𝐙𝑖(𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠) for a 
set of patients 𝑖 = 1,… , 𝑛; 𝐷∗ found by Algorithm 1.  
Initialization:  divide the 3-D heart into 𝑁 indexed units 𝑠𝑘 , 𝑘 = 1, … ,𝑁; let Ω to be the 
empty set. 
For each unit 𝑠𝑘, do the following: 
1) Fit a GLM with 𝑉𝐷∗
(𝑠𝑘) and 𝐙 as predictors 
2) If the coefficient for 𝑉𝐷∗
(𝑠𝑘) is significantly greater than zero, add 𝑠𝑘 to Ω.  
Output: Ω as the hot spot 𝑟∗. 
 
4.5 Case Study 
Our dataset contains 134 patients with stage III NSCLC who were treated at Mayo 
Clinic Arizona. All the patients were treated with Intensity Modulated Radiation Therapy 
(IMRT). The 3-D dose map of the heart for each patient was retrieved from treatment 
planning software. We consider the 3-D heart to be composed by 64 units, i.e., 4 equally 
spaced intervals in each of the x, y, and z directions. We focus on finding the hot spot 
significantly associated with OS, i.e., the GLM included in our hot spot search algorithm 
is a Cox model. Three covariates were included in the Cox model, including age, stage of 
the lung cancer, and use of chemotherapy, according to the AIC criterion. Average follow-
up time of these patients is 1.5 years with 53/81 patients being alive/deceased at the time 
of the follow-up.  
To find the hot spot, we first use Algorithm 1 on the whole heart and find the 
optimal dose threshold 𝐷∗ . 𝐷∗  is found to be 54.88 𝐺𝑦. Then, under this 𝐷∗ , we use 
78 
 
Algorithm 2 and find the hot spot sub-region, 𝑟∗ , which consists of 19 units that are 
connected and located at the right-superior of the heart. Fig. IV.2 shows locations of the 19 
units on the heart that are highlighted in red. Different shades of red are used to show the 
significant level of each unit in association with OS in the Cox model.  
Furthermore, we fit a Cox model with 𝑉𝐷∗
(𝑟∗)
 and the three aforementioned 
covariates, with 𝐷∗ = 54.88 𝐺𝑦  and 𝑟∗  being the hot spot that includes the 19 units 
highlighted in Fig. 4.2. The coefficient of 𝑉𝐷∗
(𝑟∗)
 in this Cox model is 4.33 with p value = 
0.0005. The positiveness of the coefficient means that the more fractional volume of the 
hot spot sub-region with dose greater than 54.88 𝐺𝑦, the higher the risk of death. The small 
p value means that this relationship holds with high confidence. Specifically, we show the 
survival curves of two patients with the same covariates (both are 68 years old, underwent 
chemotherapy, and had stage III-b lung cancer) but different values for 𝑉𝐷∗
(𝑟∗)
, i.e., 𝑉𝐷∗
(𝑟∗)
=
0 and 0.39 for patient A and B, respectively.  It is clear from Fig. 3 that patient B has lower 
survival probability (higher risk of death) than A.  
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Figure 4.2: Hot spot sub-region found by the proposed search algorithm overlaid on CT 
volume of the heart (the hot spot sub-region consists of 19 units highlighted in red of two 
different shades used to represent different p-value ranges in the Cox model coefficients 
corresponding to the units).  
 
Figure 4.3: Survival curves of two patients with the same covariates but different 𝑉𝐷∗
(𝑟∗)
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Interpretation of the Hot Spot: As shown in Fig. 4.2, location of the hot spot is at the right-
superior of the heart. This sub-region harbors a crucial structure, known as the sinoatrial 
(SA) node of the electronic conduction system of the heart (James, 1961). The SA node 
generates electronic signals and stimulates the heart to contract so that the heart can pump 
normally. From our findings, we suspect that radiation dose may cause injury on the SA 
node and therefore disrupt the normal function of the electronic conduction system of the 
heart, which further shorten OS. The potential risk of radiation dose on the electronic 
conduction system has been reported in the literature (Darby et al., 2013; Jaworski et al., 
2013).   
Comparison Experiments: For comparison purposes, we apply two commonly adopted 
approaches for studying cardiac toxicity to the same dataset as the proposed algorithm. One 
approach is to fit a Cox model with covariates and 𝑉𝐷  extracted from the whole heart 
(Johnson, 2017). We try different values for 𝐷 and find the most significant one happens 
at 𝐷 = 55𝐺𝑦 with p value =0.04. This p value is far less significant than that corresponds 
to the hot spot found by our algorithm (p=0.0005). Another commonly used approach is to 
segment the heart into four anatomically-defined compartments, i.e., left ventricle, left 
atrium, right ventricle and right atrium (Kang et al., 2012). Then, a Cox model is fit for 
each compartment using 𝑉𝐷  extracted from that compartment and covariates. We try 
different values for 𝐷 and find the most significant one happens at 𝐷 = 55𝐺𝑦 with p value 
=0.024 for compartment right ventricle. This p value is more significant than the one 
obtained from the whole heart analysis, but still far less significant than that corresponds 
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to the hot spot found by our algorithm. These results using the existing approaches 
demonstrate the utility of the proposed hot spot search algorithm.   
4.6 Conclusion 
In this paper, we developed the mathematical formulation and associated 
algorithms for searching the hot spot of the heart susceptible to cardiac toxicity and 
subsequently shortening OS for patients with lung cancer under RT. Our finding of 
applying the algorithms to real data revealed that the hot is located at the right-superior of 
the heart, which harbors the SA node that is crucial to the heart function. This explained 
the mechanism as to how radiation damages the heart. The found location and extent of the 
hot spot together with the dose threshold may be included in the treatment planning 
software as constraints to help optimize the treatment plan to maximally kill cancer cells 
while minimizing cardiac toxicity. Future work may include applying the hot spot search 
algorithms to study direct measures of cardiac toxicity and integration of the hot spot search 
with treatment optimization.   
 
 
 
 
 
 
 
 
82 
 
CHAPTER 5 
CONCLUSIONS  
 
In healthcare, rich datasets have been available from multiple heterogeneous 
sources or modalities. There is great need for heterogeneous data fusion to leverage the 
information from different modalities to make better diagnosis or prognosis in healthcare. 
Although it is a promising method, there are several challenges in healthcare application. 
In Chapter 2, we proposed a bio-statistical hybrid model for integration of 3-D dose map 
and patient characteristics in prediction of rectal toxicity of prostate cancer patients who 
receives IMRT. In Chapter 3, we proposed an IMTL model to deal with missing modality 
problem. And in Chapter 4, we proposed a hotspot search algorithm for the fusion of 3-D 
radiation dosemap and patient characteristics to predict the overall survival of the patients. 
The proposed algorithm divided the 3-D heart dose map into several regions, determined 
the dosimetric/volumetric features in each sub region and finally identified the hotspots of 
the heart which is associated with overall survival given the patient characteristics. My 
dissertation provided the first-of-its-kind rigorous statistical models to multi-modality 
heterogeneous data fusion, which worked well in the specific application domain. Future 
work may include the feature selection method in the novel heterogeneous data fusion 
methods.  
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1. Proof of Proposition 1:  
Let 𝑎 = 1/𝑛 and 𝐷 = max
𝑖
𝐷𝑖. By definition, 𝐷𝑖 ≤ D for ∀𝑖. Therefore, (∑ 𝑣𝑖𝐷𝑖
𝑎
𝑖 )
1/𝑎 ≤
(∑ 𝑣𝑖𝐷
𝑎
𝑖 )
1/𝑎 = 𝐷, i.e., 
limsup
𝑎→∞
 (∑ 𝑣𝑖𝐷𝑖
𝑎
𝑖 )
1/𝑎 ≤ 𝐷.                                           (A-1) 
Furthermore, let 𝑆𝛿 = {𝑖|𝐷 ≤ 𝐷𝑖 + 𝛿}. Then, (∑ 𝑣𝑖𝐷𝑖
𝑎
𝑖 )
1/𝑎 ≥ (∑ 𝑣𝑖𝑖∈𝑆𝛿 )
1/𝑎(𝐷 − 𝛿). By 
letting 𝛿 → 0 and 𝑎 → ∞, we can get 
liminf
𝑎→∞
 (∑ 𝑣𝑖𝐷𝑖
𝑎
𝑖 )
1/𝑎 ≥ 𝐷.                                             (A-2) 
Combining (A-1) and (A-2), we get lim
𝑎→∞
(∑ 𝑣𝑖𝐷𝑖
𝑎
𝑖 )
1/𝑎 = 𝐷.                                                          
∆ 
2. Proof of Proposition 2:  
If 𝛼𝑝+1
∗ ≥ 0, the constraint in the optimization problem in (9) is automatically satisfied by 
the optimal solution to the unconstrained optimization problem. This means that the 
optimal solution to the unconstrained problem is just that to the constrained problem, i.e., 
(?̂?0, … , ?̂?𝑝+1) = (𝛼0
∗ , … , 𝛼𝑝+1
∗ ).  
If 𝛼𝑝+1
∗ < 0, let 𝜶∗ = (𝛼0
∗, ⋯ , 𝛼𝑝+1
∗ ) and ?̂? = (?̂?0,⋯ , ?̂?𝑝+1) be the optimal solutions to 
the unconstrained and constrained optimization problems, respectively. We need to prove 
that (?̂?0, … , ?̂?𝑝) = (𝛼0
∗ , … , 𝛼𝑝
∗) and ?̂?𝑝+1 = 0. To prove this, we start by constructing a 
feasible solution to the constrained optimization in (9), i.e., 
?̃? = 𝛽?̂? + (1 − 𝛽)𝜶∗,                                             (A-3) 
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where 𝛽 = −
𝛼𝑝+1
∗
?̂?𝑝+1− 𝛼𝑝+1
∗ . Here, 𝛽  is valid because we have known that 𝛼𝑝+1
∗ < 0  and 
?̂?𝑝+1 ≥ 0 such that the denominator of 𝛽 must not be zero. Also, ?̃? is a feasible solution 
to (9) because 
              ?̃?𝑝+1 = 𝛽?̂?𝑝+1 + (1 − 𝛽)𝛼𝑝+1
∗ = 0,                                (A-4) 
which satisfies the constraint in (9). Then, the following inequality holds: 
𝑔(?̃?) ≥ 𝑔(?̂?) ≥ 𝑔(𝜶∗).                                         (A-5) 
The first “≥” in (A-5) holds because ?̃? is a feasible solution and ?̂? is the optimal solution. 
The second “≥” holds because ?̂? is the optimal solution to the constrained optimization 
while 𝜶∗ is that to the unconstrained optimization.  
Furthermore, let  𝑔(𝛼0, ⋯ , 𝛼𝑝+1) = −𝑙(𝛼0, ⋯ , 𝛼𝑝+1) + 𝜆 ∑ |𝛼𝑘|
𝑝
𝑘=1 , which is the 
objective function of (9). 𝑔(∙) a convex function. Therefore, we can get 
𝑔(?̃?) = 𝑔(𝛽?̂? + (1 − 𝛽)𝜶∗) 
≤ 𝛽𝑔(?̂?) + (1 − 𝛽)𝑔(𝜶∗) 
                                                      ≤ 𝛽𝑔(?̂?) + (1 − 𝛽)𝑔(?̂?) = 𝑔(?̂?).                        (A-6) 
The fact that 𝑔(?̃?) ≥ 𝑔(?̂?) in (A-5) and 𝑔(?̃?) ≤ 𝑔(?̂?) in (A-6) leads to 𝑔(?̃?) = 𝑔(?̂?). 
This means that ?̃?  is the optimal solution to (9), i.e., ?̂? = ?̃?. Then, ?̂?𝑝+1 = ?̃?𝑝+1 = 0 
according to (A-4). Furthermore, using (A-3), we can get (?̂?0, … , ?̂?𝑝) = (𝛼0
∗ , … , 𝛼𝑝
∗) .                                                
∆ 
3. Proof of Proposition 5:  
Let  ?̂? be the maximum likelihood estimator for the linear coefficients 𝛃 in a generalized 
linear model (GLM). It can be derived that under a finite sample size, the bias of ?̂? is 
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𝑏𝑖𝑎𝑠(?̂?) = (𝐗𝑇𝐖𝐗)−1𝐗𝑇𝐖𝛏.                                             (A-7) 
Here, 𝐗𝐓𝐖𝐗 = −𝐸[
𝜕2𝑙(𝛃)
𝜕𝛃𝜕𝛃𝑇
], where 𝑙(𝛃) is the log-likelihood function. The 𝑗-th element of 
𝛏  is 𝜉𝑗 = −
1
2
𝜇𝑗
′′
𝜇𝑗
′ 𝐐𝑗𝑗 , where 𝜇𝑗
′ = 𝜕𝜇𝑗/𝜕𝜂𝑗 , 𝜇𝑗
′′ = 𝜕2𝜇𝑗/𝜕𝜂𝑗
2 , 𝜇𝑗  is the mean of the 
distribution from the exponential family the GLM corresponds to, 𝜂𝑗 is the linear predictor 
of the GLM, and 𝐐𝑗𝑗 is the 𝑗-th diagonal element of matrix 𝐐 = 𝐗(𝐗
𝐓𝐖𝐗)−1𝐗𝐓. Next, we 
use the result in (A-7) to derive the bias of our model, i.e., 𝑏𝑖𝑎𝑠(?̌?).  
Specifically, the log-likelihood function of our model, 𝑙𝑛∗
𝑤 (𝛂), is given in (12). The first 
derivative of 𝑙𝑛∗
𝑤 (𝛂) is  
𝜕𝑙𝑛∗
𝑤 (𝛂)
𝜕𝛂
= ∑ {
𝑤1𝑦𝑗
𝜙(𝜂𝑗)
−
𝑤0(1−𝑦𝑗)
1−𝜙(𝜂𝑗)
}𝑁𝑗=1 𝜑(𝜂𝑗)𝐱𝑗 =
∑ {
[𝑤1𝑦𝑗−𝑤0𝜙(𝜂𝑗)]−(𝑤1−𝑤0)𝑦𝑗𝜙(𝜂𝑗) 
𝜙(𝜂𝑗)(1−𝜙(𝜂𝑗))
}𝑁𝑗=1 𝜑(𝜂𝑗)𝐱𝑗 , 
where 𝐱𝑗 is the 𝑗-th column of 𝐗. Furthermore, we can get 
              𝐗𝐓𝐖𝐗 = −𝐸 [
𝜕2𝑙𝑛∗
𝑤 (𝛂)
𝜕𝛂𝜕𝛂𝑇
] = ∑ {
𝑤0𝜙(𝜂𝑗)+𝑤1(1−𝜙(𝜂𝑗))
𝜙(𝜂𝑗)(1−𝜙(𝜂𝑗))
}𝑁𝑗=1 𝜑
2(𝜂𝑗)𝐱𝑗𝐱𝑗
𝑇 .             
(A-8) 
It is clear from (A-8) that 𝐖 is a diagonal matrix with the 𝑗-th element being 
𝐖𝑗𝑗 =
𝑤0𝜙(𝜂𝑗)+𝑤1(1−𝜙(𝜂𝑗))
𝜙(𝜂𝑗)(1−𝜙(𝜂𝑗))
𝜑2(𝜂𝑗).                                    (A-9) 
Next, to derive 𝜉𝑖, we need to derive 𝜇𝑖
′ and 𝜇𝑖
′′ for our model. Specifically, 𝜇𝑖 = 𝜙(𝜂𝑖)
𝑤1. 
Therefore, the first derivative of 𝜇𝑖 is  
𝜇𝑖
′ = 𝑤1𝜙(𝜂𝑖)
𝑤1−1𝜑(𝜂𝑖),     
and the second derivative of 𝜇𝑖 is 
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𝜇𝑖
′′ = −𝑤1𝜙(𝜂𝑖)
𝑤1−1𝜑(𝜂𝑖)𝜂𝑖 + 𝑤1(𝑤1 − 1)𝜙(𝜂𝑖)
𝑤1−2𝜑2(𝜂𝑖). 
Therefore,  
𝜉𝑗 = −
1
2
𝜇𝑗
′′
𝜇𝑗
′ 𝐐𝑗𝑗 =
𝜂𝑗𝜙(𝜂𝑗)−(𝑤1−1)𝜑(𝜂𝑗)
2𝜙(𝜂𝑗)
𝐐𝑗𝑗 .                           (A-10) 
Finally, by inserting (A-9) and (A-10) into (A-7), we can obtain the 𝑏𝑖𝑎𝑠(?̌?) in (13).                  
∆ 
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Proof of Theorem 1 
Under IMTL, the complete-data log-likelihood function is: 
𝑙𝑙ℎ𝐼𝑀𝑇𝐿  = 𝐿1 + 𝐿2,                                                    (B-1) 
where  
𝐿1 = −
𝑛1
2
log|𝚺| −
1
2
∑ (𝑥𝑖
(21) − 𝐱𝑖
(11)𝐀2 − 𝑏2, 𝑦𝑖
(1) −   𝐱𝑖
(11)𝛃1 −
𝑛1
𝑖=1
𝛽0) 𝚺
−1 (
𝑥𝑖
(21)
−𝐱𝑖
(11)
𝐀2−𝑏2
𝑦𝑖
(1)
−𝐱𝑖
(11)
𝛃1−𝛽0
),  
𝐿2 = −
𝑛2
2
log|𝚺| −
1
2
∑ (𝑥𝑖
(22) − 𝐱𝑖
(12)𝐀2 − 𝑏2, 𝑦𝑖
(2) −   𝐱𝑖
(12)𝛃1 −
𝑛2
𝑖=1
𝛽0) 𝚺
−1 (
𝑥𝑖
(22)
−𝐱𝑖
(12)
𝐀2−𝑏2
𝑦𝑖
(2)
−𝐱𝑖
(12)
𝛃1−𝛽0
). 
Let 𝐷𝑜𝑏𝑠 = {𝐱𝑖
(11) , 𝐱𝑖
(12), 𝑥𝑖
(22), 𝑦𝑖
(1), 𝑦𝑖
(2)| 𝑖 = 1,… , 𝑛} and 𝐷𝑚𝑖𝑠 = {𝑥𝑖
(21)|𝑖 = 1,… , 𝑛} 
denote the observed and missing data in (B-1). The observed Fisher information for each 
element 𝜃𝑖𝑗  in 𝛀 is: 
𝜁𝐼𝑀𝑇𝐿(𝜃𝑖𝑗|𝐷𝑜𝑏𝑠) = 
                       −
𝜕2 𝑙𝑙ℎ𝐼𝑀𝑇𝐿
𝜕𝜃𝑖𝑗
2 − 𝐸𝐷𝑚𝑖𝑠 {(
𝜕 𝑙𝑙ℎ𝐼𝑀𝑇𝐿
𝜕𝜃𝑖𝑗
)
2
|𝐷𝑜𝑏𝑠} + 𝐸𝐷𝑚𝑖𝑠 (
𝜕 𝑙𝑙ℎ𝐼𝑀𝑇𝐿
𝜕𝜃𝑖𝑗
| 𝐷𝑜𝑏𝑠)
2
.  
Through some algebra, we can derive 𝜁𝐼𝑀𝑇𝐿(𝜃𝑖𝑗|𝐷𝑜𝑏𝑠) as  
𝜁(𝜃22|𝐷𝑜𝑏𝑠)𝑀𝑀𝑇𝐿 =
1
2
𝑛2𝜎22
2 + (2?̃?1 − 𝑛1)(𝜎2𝑦
2 𝜎𝑦𝑦⁄ )𝜎22 + 2(𝑛1 − ?̃?1)(𝜎2𝑦
2 𝜎𝑦𝑦⁄ )
2
−
1
2
𝑛1𝜎22
2 ,   (B-2) 
𝜁(𝜃2𝑦|𝐷𝑜𝑏𝑠)𝑀𝑀𝑇𝐿 =
1
2
𝑛2(𝜎22𝜎𝑦𝑦 + 𝜎2𝑦
2 ) +
1
2
(𝑛1 − ?̃?1)𝜎22𝜎𝑦𝑦 +
1
2
(𝑛1 + ?̃?1)𝜎2𝑦
2 ,    (B-3) 
𝜁(𝜃𝑦𝑦|𝐷𝑜𝑏𝑠)𝑀𝑀𝑇𝐿 =
1
2
(𝑛1 + 𝑛2)𝜎𝑦𝑦
2 ,                                                      (B-4) 
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where 
?̃?1 =
1
𝜎𝑦𝑦
∑ (𝑦𝑖
(1) − 𝐱𝑖
(11)𝛃1 − 𝛽0)
2
𝑛1
𝑖=1 . 
Under the two-modality IMD, SM and AADM has the same log-likelihood function: 
𝑙𝑙ℎ𝑆𝑀 = 𝑙𝑙ℎ𝐴𝐴𝐷𝑀 = 𝐿2. We can derive their observed Fisher information (only SM is 
shown here): 
𝜁(𝜃22|𝐷𝑜𝑏𝑠)𝑆𝑀 =
1
2
𝑛2𝜎22
2 ,                                                                    (B-5) 
𝜁(𝜃2𝑦|𝐷𝑜𝑏𝑠)𝑆𝑀 =
1
2
𝑛2(𝜎22𝜎𝑦𝑦 + 𝜎2𝑦
2 ),                                                (B-6) 
𝜁(𝜃𝑦𝑦|𝐷𝑜𝑏𝑠)𝑆𝑀 =
1
2
𝑛2𝜎𝑦𝑦
2 .                                                                    (B-7) 
Furthermore, taking the expectation of (B-2) through (B-7) with respect to 𝐷𝑜𝑏𝑠, we can 
get the Fisher information, 𝐼𝐼𝑀𝑇𝐿(𝜃𝑖𝑗) and 𝐼𝑆𝑀(𝜃𝑖𝑗). Subtracting the respective Fisher 
information of the two models, we have  
𝐼𝐼𝑀𝑇𝐿(𝜃22) − 𝐼𝑆𝑀(𝜃22) = (𝑛1 − 2𝑝1)(𝜎2𝑦
2 𝜎𝑦𝑦⁄ )𝜎22 + 2𝑝1(𝜎2𝑦
2 𝜎𝑦𝑦⁄ )
2
−
1
2
𝑛1𝜎22
2 ,     (B-8) 
𝐼𝐼𝑀𝑇𝐿(𝜃2𝑦) − 𝐼𝑆𝑀(𝜃2𝑦) = 𝑛1𝜎2𝑦
2 +
1
2
𝑝1|𝚺|,                       (B-9) 
𝐼𝐼𝑀𝑇𝐿(𝜃2𝑦) − 𝐼𝑆𝑀(𝜃2𝑦) =
1
2
𝑛1𝜎𝑦𝑦
2  .                                  (B-10) 
(B-8) and (B-9) are positive. Therefore, 𝐼𝐼𝑀𝑇𝐿(𝜃𝑖𝑗) > 𝐼𝑆𝑀(𝜃𝑖𝑗) if (B-8) is positive, i.e.,  
                         
−𝑛1+2𝑝1+√(𝑛1−2𝑝1)
2+𝑛1𝑝1
4𝑝1
<
𝜎2𝑦
2
𝜎22𝜎𝑦𝑦
.                                              ∎  
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Proof of Proposition 1 
Let 𝐻 denote the whole heart. With 𝑟∗ denoting the sub-region of 𝐻 corresponding to the 
hot spot, let 𝑟𝑐
∗ denote the rest of 𝐻 excluding 𝑟∗. Furthermore, let 𝑥(𝐻), 𝑥(𝑟
∗), and 𝑥(𝑟𝑐
∗) 
denote the dose variable defined for 𝐻 , 𝑟∗ , and 𝑟𝑐
∗ . Let 𝑓(𝑥(𝐻)), 𝑓(𝑥(𝑟
∗))𝑎𝑛𝑑 𝑓(𝑥(𝑟𝑐
∗)) 
denote the probability distributions of these variables. Empirical distributions of these 
variables can be obtained by the DVHs computed from the 3-D dose map of the whole 
heart, localized to 𝑟∗, and localized to 𝑟𝑐
∗, respectively. According to the definitions of these 
variables, we know that 𝑓(𝑥(𝐻)) is a mixed distribution of , 𝑓(𝑥(𝑟
∗)) and 𝑓(𝑥(𝑟𝑐
∗)) in the 
form of 
𝑓(𝑥(𝐻)) = 𝜋𝑓(𝑥(𝑟
∗)) + (1 − 𝜋)𝑓(𝑥(𝑟𝑐
∗)), 
which leads to 
𝑃(𝑥(𝐻) > 𝐷∗) = 𝜋𝑃(𝑥(𝑟
∗) > 𝐷∗) + (1 − 𝜋)𝑃(𝑥(𝑟𝑐
∗) > 𝐷∗) 
i.e.,  
𝑉𝐷∗
(𝐻)
= 𝜋𝑉𝐷∗
(𝑟∗)
+ (1 − 𝜋)𝑉𝐷∗
(𝑟𝑐
∗)
. 
Taking the partial covariance between 𝑔(𝜇) and 𝑉𝐷∗
(𝐻)
, we can get 
𝐶𝑜𝑣(𝑔(𝜇), 𝑉𝐷∗
(𝐻)
|𝐙  ) = 𝜋𝐶𝑜𝑣 (𝑔(𝜇), 𝑉𝐷∗
(𝑟∗)
|𝐙  ) + (1 − 𝜋)𝐶𝑜𝑣 (𝑔(𝜇), 𝑉𝐷∗
(𝑟𝑐
∗)
|𝐙  ) 
𝐶𝑜𝑣 (𝑔(𝜇), 𝑉𝐷∗
(𝑟∗)
|𝐙  ) > 0  by the definition of a hot spot (i.e., Definition 1). 
𝐶𝑜𝑣 (𝑔(𝜇), 𝑉𝐷∗
(𝑟𝑐
∗)
|𝐙  ) ≥ 0. Therefore, we have 𝐶𝑜𝑣(𝑔(𝜇), 𝑉𝐷∗
(𝐻)
|𝐙  ) > 0.         Δ 
 
 
 
